Recombinant alkaline phosphatase for treating acute respiratory distress syndrome
By administering alkaline phosphatase, particularly RecAP, to ARDS patients, the problem of poor efficacy in treating ARDS with existing technologies has been solved, significantly improving the P/F ratio and lung function, reducing mortality, and improving patient prognosis.
Patent Information
- Application Number
- CN202410988373.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2021-06-10
- Filing Date
- 2021-09-09
- Publication Date
- 2024-11-12
AI Technical Summary
There is a lack of effective treatments for acute respiratory distress syndrome (ARDS) in the current technology, especially in intensive care units where mechanical ventilation is of limited effectiveness and has a mortality rate as high as 35%-50%.
Alkaline phosphatase (AP), especially recombinant alkaline phosphatase (RecAP), is administered to ARDS patients at doses ranging from 500 U/kg to 2,000 U/kg via intravenous infusion. This is used to prevent or treat ARDS, improve the patient's P/F ratio, shorten the duration of mechanical ventilation, and reduce lung injury caused by viral infection.
It significantly improved the P/F ratio in ARDS patients, reduced the duration of mechanical ventilation, decreased mortality, and improved patients' lung function and quality of life.
Smart Images

Figure BDA0004958149860000191 
Figure HDA0004958149870000011 
Figure HDA0004958149870000021
Abstract
Description
[0001] The present invention relates to the field of medicine. In particular, the present invention relates to alkaline phosphatase, and in particular the use of improved alkaline phosphatase (such as RecAP) for preventing, treating, curing or alleviating symptoms of acute respiratory distress syndrome (ARDS). The present invention also relates to methods for preserving lung function, shortening the duration of mechanical ventilation therapy, and increasing the P / F ratio. background
[0002] Acute respiratory distress syndrome (ARDS) is a pulmonary respiratory dysfunction characterized by widespread inflammation of the lungs. Symptoms include shortness of breath, rapid breathing, and bluish skin (Fan, E; Brodie, D; Slutsky, AS (February 20, 2018). "Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment". JAMA. 319 (7): 698–710). The overall prognosis of ARDS is poor, with a mortality rate of approximately 40% (Lewis, Sharon R.; Pritchard, Michael W.; Thomas, Carmel M.; Smith, Andrew F. (July 23, 2019). "Pharmacological agents for adults with acute respiratory distress syndrome". The Cochrane Database of Systematic Reviews. 7: CD004477). For those who survive ARDS, a decline in quality of life is common (Matthay, MA; Zemans, RL; Zimmerman, GA; Arabi, YM; Beitler, JR; Mercat, A; Herridge, M; Randolph, AG; Calfee, CS (2019, March 14). "Acuterespiratory distress syndrome". Nature Reviews. Disease Primers. 5(1):18).
[0003] ARDS affects more than 3 million people worldwide each year (Fan E et al. (2018)). Although the term "adult respiratory distress syndrome" is sometimes used to distinguish ARDS from "infant respiratory distress syndrome" in newborns, international consensus is that "acute respiratory distress syndrome" is the best term because ARDS affects people of all ages (Bernard G, Artigas A, Brigham K, Carlet J, Falke K, Hudson L, Lamy M, Legall J, Morris A, Spragg R (1994). "The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination". Am J Respir Crit Care Med. 149(3 Pt 1): 818–24). There are separate diagnostic criteria for children and those in less resourced parts of the world (Matthay MA et al. (2019)).
[0004] The annual incidence of ARDS is generally 13–23 per 100,000 people in the general population. ARDS is more common in mechanically ventilated people with acute lung injury (Lewandowski K, Lewandowski M (2006). "Epidemiology of ARDS". Minerva Anestesiol. 72(6):473–7). In 2020, the incidence of ARDS increased due to COVID-19 (Guo, YR; Cao, QD; Hong, ZS; Tan, YY; Chen, SD; Jin, HJ; Tan, KS; Wang, DY; Yan, Y (March 13, 2020). "The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19)outbreak-an update on the status". Military Medical Research. 7(1):11; Solaimanzadeh, I (March 20, 2020). "Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)". Cureus. 12(3):e7343).
[0005] Globally, and in the absence of a viral pandemic such as COVID-19, acute sepsis is the most common trigger for ARDS (Goldman, Lee (2011). Goldman's Cecil Medicine (24th ed.). Philadelphia: Elsevier Saunders. p. 635. ISBN 978-1437727883). Other triggers include mechanical ventilation, pneumonia, Gilchrist's disease, drowning, circulatory shock, aspiration, trauma—especially pulmonary contusion—major surgery, massive blood transfusion (Laar, Alexander PJ; Binnekade, Jan M.; Prins, David; van Stein, Danielle; Hofstra, Jorrit J.; Schultz, Marcus J.; Juffermans, Nicole P. (March 2010). "Risk factors and outcome of transfusion-related acute lung injury in the critically ill: Anested case–control study*". Critical Care Medicine. 38(3):771–778), smoke inhalation, drug reaction or overdose, fat embolism, and reperfusion pulmonary edema after lung transplantation or pulmonary embolectomy.
[0006] In addition to treatment of the underlying cause (such as antibiotics or antiviral or anti-inflammatory drugs), ARDS is typically treated with mechanical ventilation in the intensive care unit (ICU). Mechanical ventilation is usually delivered through a rigid tube that is passed into the mouth and secured in the airway (endotracheal tube), or through a tracheostomy when prolonged ventilation (≥2 weeks) is required. The role of non-invasive ventilation is limited to the very early stages of the disease, or to prevent worsening respiratory distress in individuals with atypical pneumonia, lung bruises, or major surgical patients who are at risk for developing ARDS. No specific ventilator mode is known to improve the mortality rate of ARDS, which is between 35%–50% (Fan E et al. (2018)). Therefore, methods of treating ARDS are needed. Overview
[0007] The present disclosure provides a method of treating acute respiratory distress syndrome (ARDS) in a subject in need thereof, comprising administering to the subject an effective amount of alkaline phosphatase (AP). In a preferred embodiment, AP is administered in at least one dose of 500 U / kg to 2,000 U / kg.
[0008] The severity of ARDS is often classified as "mild," "moderate," and "severe" ARDS. Mild, moderate, and severe ARDS are defined in this article using the following criteria: A decrease in the PaO2 / FiO2 ratio (the PaO2 / FiO2 ratio is the ratio of the partial pressure of arterial oxygen (PaO2, expressed in mmHg) to the fraction of inspired oxygen (FiO2, expressed as a fraction, not a percentage) and is also called the P / F ratio) as follows: ->200 and ≤300 mmHg (>26.66 kPa and ≤40.00 kPa): mild ARDS; ->100 and ≤200 mmHg (>13.33 and ≤26.66 kPa): moderate ARDS; -≤100 mmHg (≤13.33 kPa): severe ARDS; The P / F ratio was measured using a minimum positive end-expiratory pressure (PEEP) of 5 cmH2O.
[0009] In some aspects, prior to treatment with AP, the subject suffers from severe or moderate ARDS according to the above definition (i.e., a P / F ratio of ≤200 mmHg using a minimum PEEP of 5 cmH2O). In some aspects, prior to treatment with AP, the subject suffers from severe ARDS (i.e., a P / F ratio of ≤100 mmHg using a minimum PEEP of 5 cmH2O). In some aspects, prior to treatment with AP, the subject suffers from moderate ARDS (i.e., a P / F ratio of 100–200 mmHg using a minimum PEEP of 5 cmH2O). In some aspects, ARDS is associated with and / or caused by sepsis. In other aspects, ARDS is associated with and / or caused by viral infection, preferably coronavirus infection, more preferably severe acute respiratory syndrome (SARS)-associated coronavirus infection, preferably severe acute respiratory syndrome (SARS)-associated coronavirus infection. In some aspects, AP is human AP. In some aspects, AP is recombinant AP. In some aspects, recombinant AP is chimeric. In some aspects, the chimeric AP has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to RecAP (SEQ ID NO: 1).
[0010] In some aspects, the increase in respiratory function comprises an increase in the P / F ratio of the subject relative to the P / F ratio of the subject without treatment. In some aspects, sepsis in the subject is detected less than 96 hours prior to AP administration. In some aspects, sepsis is detected less than 72 hours prior to detection of ARDS.
[0011] In some aspects, treatment according to the invention is initiated within 24 hours after detecting sepsis in the subject. In some aspects, treatment according to the invention is initiated within 24 hours after detecting ARDS in the subject. In some aspects, AP is administered once a day. In some aspects, AP is administered intravenously. In some aspects, P administers A at a dose of three times a day. In some aspects, the dose of the AP is 0.8 mg / kg or 1.6 mg / kg of RecAP (e.g., clinical grade RecAP used in the present disclosure). In some aspects, the dose of the AP is 500 U / kg or 1000 U / kg of RecAP (e.g., clinical grade RecAP used in the present disclosure).
[0012] In some aspects, administration of at least one dose of AP results in a reduction in duration or cessation of mechanical ventilation therapy for a subject undergoing mechanical ventilation therapy. In some aspects, administration of at least one dose of AP results in maintenance or increase in the subject's P / F ratio. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 is a table showing proposed RecAP dosage groups.
[0014] Figure 2 The amino acid sequence of RecAP is shown (SEQ ID NO: 1).
[0015] Figure 3 Shown is the timeline of the STOP-AKI study, which included the determination of the AUC 1-7 , RRT incidence and mortality, and the dosage regimen and time frame of MAKE.
[0016] Figure 4 is a flow chart showing the enrollment, randomization, and follow-up of patients in the trial. Abbreviations: AKI (acute kidney injury), AUC (time-corrected area under the curve), ECC (endogenous creatinine clearance), ICF (informed consent), ITT (intention to treat), IV (intravenous), MAKE (major adverse renal event), NS (not specified), RecAP (human recombinant alkaline phosphatase with SEQ ID NO: 1 sequence), RRT (renal replacement therapy), SA-AKI (sepsis-associated acute kidney injury), SCr (serum creatinine).
[0017] Figure 5It is a table showing the demographic and baseline characteristics of all groups in the trial, which shows that there are no significant differences between the groups in any baseline characteristics. For variables with missing data, the data are summarized based on adjusted numbers. Body mass index (BMI) is the weight expressed in kilograms divided by the square of the height expressed in meters. The score range of Acute Physiology and Chronic Health Evaluation II (APACHE II) is 0-71, where the higher the score, the higher the severity of the disease. The Sequential Organ Failure Assessment (SOFA) score range is 0-24, where the higher the score, the more severe the functional impairment. The score range of the simplified acute physiology score (SAPS) is 0-163, and the higher the total score, the higher the severity of the disease. Estimated glomerular filtration rate (eGFR) was calculated according to the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation: 141*min(Scr / κ,1)α*max(Scr / κ,1)-1.209*0.993age*1.018[if female]*1.159[if black]. Scr is serum creatinine (mg / dL), κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.111 for males, min represents the minimum value of Scr / κ or 1, and max represents the maximum value of Scr / κ or 1. (www.kidney.org / content / ckd-epi-creatinine-equation-2009). Acute kidney injury (AKI) stage was graded according to the AKI Network definition (www.akinet.org / akinstudies.php). Median and quartile values, or numbers and percentages, are depicted.
[0018] Figure 6 Figure 2 is an AUC versus dose graph showing a linear increase in RecAP concentration. Exposures in patients in the STOP-AKI clinical trial were slightly higher than in healthy subjects. Dose linearity and proportionality were observed over the dose range (0.4–1.6 mg / kg).
[0019] Figure 7 is a table showing the primary and secondary endpoints (placebo and RecAP 0.6 mg / kg groups). AUC 1–7 The area under the ECC curve from day 1 to day 7 is expressed and divided by 7 to provide the time-corrected clearance in ml / min. Abbreviations: CI (confidence interval), CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration), ECC (endogenous creatinine clearance), eGFR (estimated glomerular filtration rate), ICU (intensive care unit), IQR (interquartile range), MAKE (major renal adverse events), RRT (renal replacement therapy), SOFA (sequential organ failure assessment). §RRT incidence represents the percentage of patients who required RRT after randomization. ∥As the last observation progresses. *MAKE 28: received RRT before or on day 28, or died before or on day 28. Proportion meeting at least one criterion. MAKE 60: eGFR estimated by the CKD-EPI formula based on serum creatinine < 60 ml / min on day 60, or need for chronic RRT before or on day 60, or death before or on day 60. Proportion meeting at least one criterion. MAKE 90:60: eGFR estimated by the CKD-EPI formula based on serum creatinine <60 ml / min on day 90, or need for chronic RRT before or on day 90, or hospitalization for new-onset AKI before or on day 90, or death before or on day 90. Proportion meeting at least one criterion. §§ indicates absolute difference (for continuous variables). represents odds ratio (for categorical variables). represents the hazard ratio (for an event).
[0020] Figure 8 Primary and secondary endpoints are shown for all treatment groups (RecAP at doses of 0.4.mg / kg, 0.8mg / kg, or 1.6mg / kg, or placebo).
[0021] Fig. 9A Quality of life (QoL) assessments measured by the EuroQoL (EQ5D) score in the ICU (left panel) and at day 90 (right panel) are shown.
[0022] Fig. 9B Pulmonary function parameters (P / F ratio, tidal volume, and PEEP) for the 1.6 mg / kg RecAP dose group and the placebo group are shown as medians. The values are shown below the graphs.
[0023] Fig. 9C Liver function parameters (alanine aminotransferase and aspartate aminotransferase activities) for the 1.6 mg / kg RecAP dose group and the placebo group are shown, expressed as medians. Values are shown below the graphs.
[0024] Fig.10 Results of post hoc multivariate analyses are shown.
[0025] Fig.11Treatment-emergent adverse events observed during the STOP-AKI study are shown.
[0026] Fig.12 P / F ratios for STOP-AKI in the population of subjects with measurable screening or day 1 values who were randomized to placebo or high-dose recAP, up to and including day 29, are shown. Numbers indicate the number of patients in each treatment group at that particular time point. Means are shown with bootstrapped 95-% confidence intervals (CLs). Times for each treatment group are slightly offset to improve discrimination of the CLs.
[0027] Fig.13 Shown are the fold changes in the P / F ratio for STOP-AKI in the population of subjects with measurable screening or day 1 values who were randomized to placebo or high-dose recAP, up to and including day 29. Numbers indicate the number of patients in each treatment group at that particular time point. Means are shown with bootstrapped 95-% confidence intervals. Times for each treatment group were slightly offset to improve discrimination of the CL.
[0028] Fig.14 The fold changes in the P / F ratio for STOP-AKI in the population of subjects with measurable screening or day 1 values who were randomized to placebo or high-dose recAP up to and including day 29 are shown. Numbers indicate the number of patients in each treatment group at that particular time point. Means are shown with bootstrapped 95-% confidence intervals. Times for each treatment group are slightly offset to improve discrimination of the CL. Mean-based data according to grouped ARDS criteria are shown in separate plots.
[0029] Fig.15 Survival is shown for STOP-AKI patients randomized to placebo or high-dose recAP, up to and including day 29. The percentage of patients alive in the placebo or high-dose AP groups for patients with severe to moderate ARDS at baseline is depicted relative to day 0. On day 0, the number of patients in the placebo group was 40 and in the high-dose recAP group was 42. Details
[0030] The object of the present disclosure is to provide a method for preserving or improving the respiratory function of a subject, especially when the subject suffers from or is at risk of acute respiratory syndrome (ARDS). Another object of the present disclosure is to prevent or shorten the duration of mechanical ventilation therapy to maintain or increase the P / F ratio of the subject, and / or increase the survival rate.
[0031] Therefore, the present disclosure relates to the use of alkaline phosphatase (AP) (e.g., RecAP) to preserve or improve respiratory function in subjects with ARDS or subjects at risk of ARDS. The present disclosure provides, for example, a method for treating a subject with severe or moderate ARDS, comprising administering an AP (e.g., RecAP) to the subject. In some aspects, each dose of the AP administered to the subject comprises at least 500 U / kg (0.8 mg / kg in the case of clinical-grade RecAP). In some specific aspects, each dose of AP is at least 1,000 U / g (1.6 mg / kg in the case of clinical-grade RecAP). In some aspects, ARDS is sepsis-associated ARDS. In other aspects, ARDS is caused or exacerbated by a viral infection, preferably a coronavirus or orthomyxovirus infection, more preferably a severe acute respiratory syndrome (SARS)-related coronavirus infection (such as, for example, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, which is the coronavirus strain that causes coronavirus disease 2019, the respiratory disease that led to the 2020 COVID-19 pandemic (COVID-19)). In the case of an orthomyxovirus infection, the infection is preferably caused by an influenza virus, such as influenza A, B, C or D, more preferably influenza A or B.
[0032] RecAP is a chimeric AP that combines the properties of two human isozymes, intestinal and placental AP (Kiffer-Moreira et al., PLoS One 2014;9:e89374). Replacing the corona domain of intestinal AP (the most biologically active isozyme of the two) with the corona domain of placental AP (which has the longest half-life) results in a highly stable, biologically active enzyme (Kiffer-Moreira et al., PLoS One 2014;9:e89374). See, e.g., U.S. Patent Application Publication Nos. US20170009216 and US20160250299, the disclosures of which are incorporated herein by reference in their entirety.
[0033] In some aspects, if ARDS is present and the ARDS has been determined to be moderate or severe, an AP (e.g., RecAP) is administered to the subject. Thus, in some aspects of the disclosure, the methods disclosed herein include measuring the severity of ARDS (e.g., by determining the P / F ratio) prior to treatment with an AP to determine whether the subject has moderate ARDS or severe ARDS.
[0034] The diagnostic criteria for ARDS continue to evolve as our understanding of the pathophysiology improves. The international consensus criteria for ARDS were most recently updated in 2012 and are referred to as the “2012 Berlin definition” (Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS (June 2012). “Acute respiratory distress syndrome: the Berlin Definition. ARDS Definition Task Force”. JAMA. 307(23):2526–33; Ferguson ND, Fan E, Camporota L, Antonelli M, Anzueto A, Beale R, Brochard L, Brower R, Esteban A, et al. (October 2012). “The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material”. Intensive Care Med. 38(10):1573–82). In addition to the overall expansion of the diagnostic threshold, other notable changes compared with the previous 1994 consensus criteria (Bernard G, Artigas A, Brigham K, Carlet J, Falke K, Hudson L, Lamy M, Legall J, Morris A, Spragg R (1994). “The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination”. Am J Respir Crit Care Med. 149(3 Pt 1):818–24) include discouraging the use of the term “acute lung injury” and defining ARDS severity levels based on the degree of reduction in oxygen levels in the blood.
[0035] According to the 2012 Berlin definition, ARDS in adults is characterized by the following: - Acute onset of lung injury within 1 week of overt clinical injury, accompanied by progression of respiratory symptoms; - Bilateral opacities on chest imaging (chest radiograph or CT) that cannot be explained by other pulmonary pathology (eg, effusions, lobar / lung collapses, or nodules); - Respiratory failure not explained by heart failure or volume overload; -Decreased PaO2 / FiO2 ratio (a decreased PaO2 / FiO2 ratio indicates decreased arterial oxygenation from available inspired gas): -Mild ARDS: >200 and ≤300 mmHg (>26.66 kPa and ≤40.00 kPa); -Moderate ARDS: >100 and ≤200 mmHg (>13.33 and ≤26.66 kPa); - Severe ARDS: ≤100 mmHg (≤13.33 kPa); Taking into account the PaO2 / FiO2 ratio, the Berlin definition requires a minimum positive end-expiratory pressure (PEEP) of 5 cmH2 O. This degree of PEEP can be delivered noninvasively using continuous positive airway pressure (CPAP) to diagnose mild ARDS.
[0036] In this regard, it is noteworthy that, as is known in the art (Hernu, R., Wallet, F., Thiollière, F. et al., An attempt to validate the modification of the American-European consensus definition of acute lung injury / acute respiratory distress syndrome by the Berlin definition in a university hospital. Intensive Care Med 39, 2161–2170 (2013)), ARDS and acute lung injury (ALI) as used herein can be used interchangeably within the limits of the above definitions, i.e., using the P / F limits and other criteria of the 2012 Berlin definition to distinguish between mild, moderate and severe disease.
[0037] In some aspects of the present disclosure, ARDS is classified as severe if the baseline P / F ratio is ≤100 mmHg. In some aspects, ARDS is classified as moderate if the baseline P / F ratio is >100 and ≤200 mmHg. In other aspects, other diagnostic measurements can be used to determine the severity of ARDS. In some aspects of the present disclosure, if ARDS is determined to be mild or absent (e.g., if the baseline P / F ratio is >200 mmHg), AP is not administered to the subject.
[0038] In some aspects, the AP (e.g., RecAP) is administered prophylactically. In some aspects, the methods disclosed herein include administering to a subject at least one dose of an AP (e.g., RecAP), wherein each dose is at least 500 U / kg (0.8 mg / kg for the clinical grade RecAP used) or 1000 U / kg (1.6 mg / kg for the clinical grade RecAP used). In some specific aspects, the dosage regimen includes administering an AP (e.g., RecAP) of 0.5 mg / kg to 2 mg / kg per day by intravenous infusion for at least three days. In some specific aspects, the dosage regimen includes administering an AP (e.g., RecAP) of 0.5 mg / kg to 2 mg / kg per day by intravenous infusion for at least three days.
[0039] In order to more readily understand the present disclosure, certain terms are first defined. Additional definitions are set forth throughout the detailed description. I. Definitions
[0040] In this specification and the appended claims, the singular forms "a / an" and "the" include plural referents unless the context clearly dictates otherwise. The terms "a / an" and the terms "one / kind or more / kind" and "at least one / kind" are used interchangeably herein.
[0041] Furthermore, "and / or" as used herein will be considered as a specific disclosure of each of the two specific features or components, regardless of whether the other features or components are present. Thus, the term "and / or" as used in phrases such as "A and / or B" herein is intended to include "A and B", "A or B", (only) "A", and (only) "B". Similarly, the term "and / or" as used in phrases such as "A, B, and / or C" is intended to cover each of the following: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; (only) A; (only) B; and (only) C.
[0042] Where aspects are described herein using the language "comprising," other similar aspects are also provided that are described in terms of "consisting of" and / or "consisting essentially of."
[0043] The term "about" used in conjunction with numerical values throughout this specification and claims indicates an interval of accuracy that is familiar and acceptable to those skilled in the art. Typically, this interval of accuracy is ±15%.
[0044] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art relevant to this disclosure.
[0045] Units, prefixes, and symbols are shown in their form recognized by the International System of Units (SI).
[0046] Numerical ranges include the numbers that define the range. In the case of a range of listed values, it should be understood that each intermediate integer value between the upper and lower limits of the range and each fraction thereof, as well as each subrange between these values, is also specifically disclosed. The upper and lower limits of any range can be independently included in or excluded from the range, and each range in which either, neither, or both limits are included is also included in the present invention. If the lower limit value is preceded by ">", the lower limit of the range will be excluded from the range. If the upper limit value is preceded by "<", the upper limit of the range will be excluded from the range. If the lower limit value is preceded by "≥", the lower limit of the range is included in the range. If the upper limit value is preceded by "≤", the upper limit of the range is included in the range. If a value is explicitly listed, it should be understood that values of approximately the same amount or quantity as the listed value are also within the scope of the present invention. If a combination is disclosed, each subcombination of the elements of the combination is also specifically disclosed and within the scope of the present invention. Conversely, if different elements or groups of elements are disclosed separately, their combinations are also disclosed. Where any element of the invention is disclosed as having multiple alternatives, examples of the invention are also disclosed herein in which each alternative is excluded, either individually or in any combination with the other alternatives; more than one element of the invention may have such exclusions, and all combinations of elements having such exclusions are disclosed herein.
[0047] As used herein, the terms "treat" or "treatment" or "treatment of" refer to (i) reducing the potential or risk of a disease or condition (e.g., ARDS), (ii) reducing the occurrence of a disease or condition (e.g., ARDS), (iii) reducing the severity of a disease or condition (e.g., ARDS) (e.g., alleviating symptoms), or (iv) a combination of the above.
[0048] For example, treatment may refer to the ability of a therapy to prevent or reduce the risk of developing lung damage caused by or associated with ARDS, and / or cure or alleviate the symptoms, signs, or causes of lung damage (e.g., ARDS), when administered to a subject. Treatment also refers to alleviating or reducing at least one clinical symptom and / or inhibiting or delaying the progression of a condition, and / or preventing or delaying the onset of a disease or illness when compared to an untreated (or placebo-treated) group. Thus, the terms "treat / treating" or "treatment of" (or grammatically equivalent terms) refer to a therapeutic treatment regimen for ARDS that can prevent (further) lung damage caused by or associated with ARDS. In the case of respiratory diseases, it is preferred that the subject has less improvement in respiratory function or less decline in respiratory function following treatment with an AP using the methods disclosed herein relative to a subject not treated with the AP.
[0049] As used herein, the term "preserving" includes preventing a decrease, slowing a decrease, stopping a decrease, and / or at least partially reversing a decrease in lung function. The term "increasing" is not necessarily limited to increasing the respiratory function to a value equal to or higher than the value before the treatment occurred. It includes partially restoring respiratory function.
[0050] As used herein, the term "subject" or "patient" refers to any subject, particularly a mammalian subject, in need of treatment or prognosis of lung injury (e.g., ARDS). As used herein, the term "subject" or "patient" includes any human or non-human animal. As used herein, phrases such as "a patient suffering from ARDS" or "a patient suffering from sepsis" include subjects (e.g., mammalian subjects) who would benefit from the administration of AP therapy as disclosed herein.
[0051] In some aspects of the present disclosure, the subject is an unexperienced subject. An unexperienced subject refers to a subject to which a therapy (e.g., a therapeutic agent) has not been administered. In some aspects, an unexperienced subject has not been treated with a therapeutic agent before being diagnosed with lung injury (e.g., ARDS) or a disease or condition (e.g., sepsis) that may cause lung injury.
[0052] In another aspect, the subject received treatment and / or one or more doses of a therapeutic agent prior to being diagnosed with lung injury (eg, ARDS) or a disease or condition that may result in lung injury and / or ARDS (eg, sepsis).
[0053] In some aspects, if the subject's baseline P / F ratio is below a predetermined P / F ratio threshold level, or if the baseline P / F ratio is within a predetermined range, at least one therapeutically effective dose of an AP (e.g., RecAP) may be administered to the subject.
[0054] The terms "therapeutic agent" and "drug" as used herein also refer to any therapeutically active substance that is administered to a subject with a disease or condition (e.g., lung injury, such as ARDS or a disease or condition that may cause lung injury (e.g., sepsis)) to produce a desired, generally beneficial effect. Therapeutic agents may also be prodrugs that, when administered to a subject, are metabolized to the desired therapeutically active substance. In some aspects, therapeutic agents are prophylactic agents. In addition, therapeutic agents may be formulated pharmaceutically. Therapeutic agents may also be or contain radioactive isotopes or agents that are activated by some other form of energy (e.g., light or ultrasound energy), or by other circulating molecules that may be administered systemically.
[0055] In some aspects of the present disclosure, therapeutic agents for treating, preventing, or ameliorating symptoms of lung injury (e.g., ARDS) or diseases or conditions that may cause lung injury (e.g., sepsis) may comprise AP (e.g., RecAP); alone or in combination with one or more standard therapeutic agents commonly used to treat lung injury (e.g., ARDS) or diseases or conditions that may cause lung injury (e.g., sepsis).
[0056] As used herein, a "therapeutically effective" amount is an amount of a therapeutic agent that provides some improvement or benefit to a subject suffering from a disease or disorder, such as lung injury, such as ARDS, or a disease or condition that may cause lung injury, such as sepsis. Thus, a "therapeutically effective" amount refers to an amount that provides some alleviation, relief, and / or reduction of at least one clinical symptom of a disease or disorder, such as lung injury, such as ARDS, or a disease or condition that may cause lung injury, such as sepsis.
[0057] Clinical symptoms related to lung injury (e.g., ARDS), or diseases or conditions (e.g., sepsis) that may cause lung injury, which can be treated by the compositions, methods, and specific dosage regimens disclosed herein, are well known to those skilled in the art. In addition, those skilled in the art will recognize that the therapeutic effect does not need to be complete or cured, as long as some benefits are provided to the object. In some aspects, the term "therapeutic effective" refers to the amount of a therapeutic agent that can change a biomarker level (e.g., a P / F ratio in a patient in need).
[0058] As used herein, "sufficient amount" or "amount sufficient" to achieve a specific outcome in a patient suffering from a disease or disorder (e.g., lung injury, such as ARDS, or a disease or condition that may result in lung injury (e.g., sepsis)) refers to an amount of a therapeutic agent (e.g., an AP, such as RecAP) effective to produce a desired effect, which is optionally a therapeutic effect (i.e., by administering a therapeutically effective amount). In some aspects, such a specific outcome is an improvement in lung function.
[0059] As used herein, the term "health care provider" refers to an individual or institution that directly interacts with and manages living subjects (e.g., human patients). Non-limiting examples of health care providers include physicians, nurses, technicians, therapists, pharmacists, counselors, alternative medicine practitioners, medical facilities, physicians' offices, hospitals, emergency rooms, clinics, urgent care centers, alternative medicine clinics / facilities, and any other entity that provides general and / or specialized treatment, assessment, maintenance, therapy, medication, and / or advice related to all or any part of a patient's health condition (including, but not limited to, general medical, specialty medical, surgical, and / or any other type of treatment, assessment, maintenance, therapy, medication, and / or advice).
[0060] As used herein, the term "clinical laboratory" refers to a facility for examining or processing materials derived from living objects (e.g., humans). Non-limiting examples of processing include biological, biochemical, serological, chemical, immunohematological, hematological, biophysical, cytological, pathological, genetic or other examinations of materials derived from the human body for the purpose of providing information, for example, for the diagnosis, prevention or treatment of any disease or injury, or for the purpose of health assessment of living objects (e.g., humans). These inspections may also include procedures for collecting or otherwise obtaining samples, preparing, determining, measuring or otherwise describing the body of a living object (e.g., a human), or the presence or absence of various substances in a sample obtained from the body of a living object (e.g., a human).
[0061] As used herein, the term "health care benefit provider" includes an individual party, organization, or group that provides, presents, confers, pays in whole or in part, or is otherwise associated with a patient's access to one or more health care benefits, benefit plans, health insurance, and / or health care expense account plans.
[0062] In some aspects, a healthcare provider may administer or instruct another healthcare provider to administer therapy to prevent, treat, or alleviate symptoms of a disease or condition, such as lung injury, such as ARDS, or a disease or condition that may lead to lung injury, such as sepsis. A healthcare provider may perform or instruct another healthcare provider or patient to perform the following actions: obtain a sample, process a sample, submit a sample, receive a sample, transfer a sample, analyze or measure a sample, quantify a sample, provide a result obtained after analyzing / measuring / quantifying a sample, receive a result obtained after analyzing / measuring / quantifying a sample, compare / score a result obtained after analyzing / measuring / quantifying one or more samples, provide a comparison / score from one or more samples, obtain a comparison / score from one or more samples, administer a therapy (e.g., an AP, such as RecAP), start administering a therapy, stop administering a therapy, continue administering a therapy, temporarily interrupt administering a therapy, increase the amount of a therapeutic agent administered, decrease the amount of a therapeutic agent administered, continue administering an amount of a therapeutic agent, increase the frequency of administering a therapeutic agent, decrease the frequency of administering a therapeutic agent, maintain the same dosing frequency of a therapeutic agent, replace a therapy or therapeutic agent by at least another therapy or therapeutic agent, and combine a therapy or therapeutic agent with at least another therapy or additional therapeutic agent.
[0063] In some aspects, a healthcare benefits provider can authorize or deny, for example, collecting a sample, processing a sample, submitting a sample, receiving a sample, transferring a sample, analyzing or measuring a sample, quantifying a sample, providing a result obtained after analyzing / measuring / quantifying a sample, transferring a result obtained after analyzing / measuring / quantifying a sample, comparing / scoring a result obtained after analyzing / measuring / quantifying one or more samples, transferring a comparison / score from one or more samples, administering a treatment or therapeutic agent, starting administration of a treatment or therapeutic agent, stopping administration of a treatment or therapeutic agent, continuing administration of a treatment or therapeutic agent, temporarily interrupting administration of a treatment or therapeutic agent, increasing the amount of a therapeutic agent administered, decreasing the amount of a therapeutic agent administered, continuing administration of an amount of a therapeutic agent, increasing the frequency of administration of a therapeutic agent, decreasing the frequency of administration of a therapeutic agent, maintaining the same frequency of administration of a therapeutic agent, replacing a treatment or therapeutic agent by at least another treatment or therapeutic agent, or combining a treatment or therapeutic agent with at least another treatment or additional therapeutic agent.
[0064] Additionally, a healthcare benefits provider may, for example, authorize or deny prescription of treatment, authorize or deny coverage of treatment, authorize or deny reimbursement of treatment expenses, determine or deny eligibility for treatment, and the like.
[0065] In some aspects, a clinical laboratory can, for example, collect or obtain samples, process samples, submit samples, receive samples, transfer samples, analyze or measure samples, quantify samples, provide results obtained after analyzing / measuring / quantifying samples, receive results obtained after analyzing / measuring / quantifying samples, compare / score results obtained after analyzing / measuring / quantifying one or more samples, provide comparisons / scores from one or more samples, obtain comparisons / scores from one or more samples, or other related activities. II. Treatment of ARDS with AP
[0066] In certain aspects, the present disclosure relates to methods for preserving or improving lung function in a subject population determined to be particularly responsive to AP therapy, particularly ARDS patients.
[0067] Analysis of data from the recent STOP-AKI study, extensively described in Pickkers et al. (Pickkers P, Mehta RL, Murray PT, et al., Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury: A Randomized Clinical Trial. JAMA. 2018; 320(19): 1998-2009), has identified a statistically significant correlation between thresholds corresponding to ARDS severity and improvement in lung function (as evidenced by an improvement in the P / F ratio relative to placebo). In the STOP-AKI clinical trial, patients were stratified according to markers of lung function, particularly the P / F ratio, and surprisingly, a particular effect of AP administration on specific subgroups was identified. One or more parameters defining each of these subgroups (e.g., a series of thresholds, such as a P / F ratio threshold) can be used, for example, to personalize AP therapy to a specific subgroup, select patients for treatment, make decisions related to AP therapy (e.g., modifying dosing or dosage schedule), or assess the likelihood of a positive outcome.
[0068] Thus, in some aspects, the methods disclosed herein involve administering an AP (e.g., RecAP) to a subject determined to have moderate or severe ARDS, comprising administering an AP (e.g., RecAP) to the subject. Technicians are familiar with how to classify the severity of a subject's ARDS as moderate or severe. As described above, the Berlin 2012 definition classifies moderate ARDS as having a P / F of >100 and ≤200 mmHg, and severe ARDS as having a P / F ≤100 mmHg (≤13.33 kPa). Thus, a person with moderate or severe ARDS has a P / F ratio of ≤200 mmHg, and the Berlin definition also requires that the minimum positive end-expiratory pressure (PEEP) be 5 cmH2O when considering the P / F ratio. In a preferred embodiment, therefore, the invention provides alkaline phosphatase (AP) for use in a method of treating acute respiratory distress syndrome (ARDS) in a subject in need thereof, wherein the subject has moderate or severe ARDS, and the P / F ratio is ≤ 200 mmHg if the P / F ratio is measured using a minimum positive end-expiratory pressure (PEEP) of 5 cmH2O. AP administration is particularly effective when administered to a subject with moderate to severe ARDS at a dose of at least 500 U / kg. AP is particularly effective when administered at a dose of at least 1,000 U / kg.
[0069] In some aspects, AP (e.g., RecAP) is administered at a dose of at least about 500 U / kg, at least about 600 U / kg, at least about 700 U / kg, at least about 800 U / kg, at least about 900 U / kg, at least about 1000 U / kg, at least about 1100 U / kg, at least about 1200 U / kg, at least about 1300 U / kg, at least about 1400 U / kg, at least about 1500 U / kg, at least about 1600 U / kg, at least about 1700 U / kg, at least about 1800 U / kg, at least about 1900 U / kg, or at least about 2000 U / kg per dose. In some aspects, AP (e.g., RecAP) is administered at a dose exceeding 2000 U / kg per dose. In some aspects, AP (e.g., RecAP) is administered at a dose below 500 U / kg per dose.
[0070] In some aspects, the AP (e.g., RecAP) is administered at a dose of about 500 U / kg to about 1500 U / kg, about 600 U / kg to about 1400 U / kg, about 700 U / kg to about 1300 U / kg, about 800 U / kg to about 1200 U / kg, or about 900 U / kg to about 1100 U / kg. In some specific aspects, the AP is administered at a dose of about 1000 U / kg.
[0071] In some aspects, the AP is a human AP. In some aspects, the AP is a recombinant AP. In some aspects, the AP is a chimeric AP. In a specific aspect, the chimeric AP is RecAP (SEQ ID NO: 1). In some aspects, the AP disclosed herein has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with the amino acid sequence of SEQ ID NO: 1. In some aspects, the AP is a functional fragment (i.e., a fragment of the AP, for example, an AP that retains at least about 10%, at least about 20%, at least about 30%, at least 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% of the AP activity of the corresponding full-length AP). In some aspects, the AP is a variant or derivative of the AP disclosed herein. Other APs that can be used as disclosed herein are discussed in detail below.
[0072] In some aspects, the AP is RecAP (e.g., clinical grade RecAP used in the present disclosure) and is administered at a dose of at least about 0.1 mg / kg, at least about 0.2 mg / kg, at least about 0.3 mg / kg, at least about 0.4 mg / kg, at least about 0.5 mg / kg, at least about 0.6 mg / kg, at least about 0.7 mg / kg, at least about 0.8 mg / kg, at least about 0.9 mg / kg, at least about 1 mg / kg, at least about 1.1 mg / kg, at least about 1.3 mg / kg, at least about 1.4 mg / kg, at least about 1.5 mg / kg, at least about 1.6 mg / kg, at least about 1.7 mg / kg, at least about 1.8 mg / kg, at least about 1.9 mg / kg, at least about 2 mg / kg, at least about 2.1 mg / kg, at least about 2.2 mg / kg, at least about 2.3 mg / kg, or at least about 2.4 mg / kg per dose. In some aspects, the AP is administered at a dosage exceeding 2.4 mg / kg per dose. In some aspects, the AP is RecAP (e.g., clinical grade RecAP used in the present disclosure), and it is administered at a dosage of at least about 100 U / kg, at least about 200 U / kg, at least about 300 U / kg, at least about 400 U / kg, at least about 500 U / kg, at least about 600 U / kg, at least about 700 U / kg, at least about 800 U / kg, at least about 900 U / kg, at least about 1000 U / kg, at least about 1100 U / kg, at least about 1200 U / kg, at least about 1300 U / kg, at least about 1400 U / kg, at least about 1500 U / kg, at least about 1600 U / kg, at least about 1700 U / kg, at least about 1800 U / kg, at least about 1900 U / kg, or at least about 2000 U / kg. The AP is RecAP and it is administered at a dose of less than 100 U / kg. The AP is RecAP and it is administered at a dose of more than 2000 U / kg.
[0073] In some aspects, the AP is RecAP (e.g., clinical grade RecAP used in the present disclosure), and is administered at a dose of about 0.8 mg / kg to about 2.4 mg / kg, about 0.9 mg / kg to about 2.3 mg / kg, about 1 mg / kg to about 2.2 mg / kg, about 1.1 mg / kg to about 2.1 mg / kg, about 1.2 mg / kg to about 2 mg / kg, about 1.3 mg / kg to about 1.9 mg / kg, about 1.4 mg / kg to about 1.8 mg / kg, or about 1.5 mg / kg to about 1.7 mg / kg. In some specific aspects, the AP is administered at a dose of about 1.6 mg / kg.
[0074] In some aspects, the AP is RecAP (e.g., clinical grade RecAP used in the present disclosure) and has a specific activity of at least about 100 U / mg, at least about 200 U / mg, at least about 300 U / mg, at least about 400 U / mg, at least about 500 U / mg, at least about 600 U / mg, at least about 700 U / mg, at least about 800 U / mg, at least about 900 U / mg, at least about 1000 U / mg, at least about 1100 U / mg, at least about 1200 U / mg, at least about 1300 U / mg, at least about 1400 U / mg, at least about 1500 U / mg, at least about 1600 U / mg, at least about 1700 U / mg, at least about 1800 U / mg, at least about 1900 U / mg, or at least about 2000 U / mg.
[0075] In some aspects, the AP is RecAP (e.g., clinical grade RecAP used in the present disclosure) and has a specific activity of about 1000U:1.6mg. In some aspects, the AP is RecAP and has a specific activity of about 600U / mg to about 700U / mg, or about 500U / mg to about 800U / mg, or about 400U / mg to about 900U / mg, or about 300U / mg to about 1000U / mg, or about 200U / mg to about 1100U / mg, or 100U / mg to about 1200U / mg. In some aspects, the AP is RecAP and has a specific activity of less than 100U / mg. In some aspects, the AP is RecAP and has a specific activity of more than 1200U / mg.
[0076] In some aspects, only one dose of an AP (e.g., RecAP) is administered per treatment (e.g., one dose per day for 1-7 days). In other aspects, more than one dose of an AP is administered. In some aspects, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 doses of an AP are administered (e.g., at least two doses per day for 1-7 days).
[0077] In some aspects, the AP dose is administered daily. In other aspects, the AP dose is administered every 2, 3, 4, 5, 6, or 7 days.
[0078] In some aspects, a single dose is administered daily. In some aspects, 2, 3 or more doses are administered daily.
[0079] In some aspects, the treatment with AP is less than about 4 days. In some aspects, the treatment with AP is less than 3 days, less than 2 days, or less than 1 day.
[0080] In certain aspects, the AP is administered at a dose of about 1000 U / kg per day for 3 consecutive days. In certain aspects, when the AP is RecAP, the AP is administered at a dose of 1.6 mg / kg per day for 3 consecutive days. In some aspects, the dosage per dose of AP (e.g., RecAP) (e.g., clinical grade RecAP used in the present disclosure) is about 0.10 mg / kg to about 3 mg / kg, or about 0.20 mg / kg to about 2.9 mg / kg, or about 0.3 mg / kg to about 2.8 mg / kg, or about 0.4 mg / kg to about 2.7 mg / kg, or about 0.5 mg / kg to about 2.6 mg / kg, or about 0.6 mg / kg to about 2.5 mg / kg, or about 0.7 mg / kg to about 2.4 mg / kg, or about 0.8 mg / kg to about 2.3 mg / kg, or about 0.9 mg / kg to about 2.2 mg / kg, or about 1 mg to about 2.1 mg / kg, or about 1.1 mg / kg to about 2 mg / kg, or about 1.2 mg / kg to about 1.9 mg / kg, or about 1.3 mg / kg to about 1.8 mg / kg, or about 1.4 mg / kg to about 1.7 mg / kg. In some aspects, the dose of each dose of AP (e.g., RecAP) comprises at least about 0.1 mg AP / kg, at least about 0.2 mg AP / kg, at least about 0.3 mg AP / kg, at least about 0.4 mg AP / kg, at least about 0.5 mg AP / kg, at least about 0.6 mg AP / kg, at least about 0.7 mg AP / kg, at least about 0.8 mg AP / kg, at least about 0.9 mg AP / kg, at least about 1 mg AP / kg, at least about 1.1 mg AP / kg, at least about 1.2 mg AP / kg, at least about 1.3 mg AP / kg, at least about 1.4 mg AP / kg, at least about 1.5 mg AP / kg, at least about 1.6 mg AP / kg, at least about 1.7 mg AP / kg, at least about 1.8 mg AP / kg, at least about 1.9 mg AP / kg, at least about 2 mg AP / kg, at least about 2.1 mg AP / kg, at least about 2.2 mg AP / kg, at least about 2.3 mg AP / kg. AP / kg, at least about 2.4 mg AP / kg, at least about 2.5 mg AP / kg, at least about 2.6 mg AP / kg, at least about 2.6 mg AP / kg, at least about 2.7 mg AP / kg, at least about 2.8 mg AP / kg, at least about 2.9 mg AP / kg or at least about 3 mg AP / kg.
[0081] The AP can be administered via different routes, such as intravenous, rectal, bronchial or oral. In some specific aspects, the AP is administered intravenously, such as via intravenous infusion. In some aspects, the AP is administered intravenously via continuous infusion.
[0082] Although short-term preservation of lung function can have immediate life-saving consequences, it is preferred that the effects of AP on lung function be long-lasting.
[0083] The P / F ratio can be determined by methods known in the art. Arterial pO2 measured by arterial blood gas (ABG) is the preferred method for calculating the P / F ratio. However, as shown in the table below, when pO2 is unknown because ABG is not available, SpO2 measured by pulse oximetry can be used to approximate pO2. It is important to note that when SpO2 is 98%-100%, the estimation of pO2 from SpO2 becomes unreliable. SpO2(%)86 87 88 89 90 91 92 93 94 95 96 97PO2(mmHg)51 52 54 56 58 6064 68 73 80 90 110 Example: Assume a patient on 40% oxygen has a pulse oximeter SpO2 of 95%. Referring to the table above, 95% SpO2 equals 80 mmHg pO2. P / F ratio = 80 divided by 0.40 = 200. The patient may be stable on 40% oxygen but still have acute respiratory failure. If the oxygen is removed and the patient is breathing room air, the pO2 will only be 40 mmHg (well below the acute respiratory failure threshold of 60 mmHg on room air).
[0084] Oxygen supplementation can be administered via a mask or nasal cannula ("NC"). A Venturi mask (Venti mask) delivers a controlled flow of oxygen at a specific fixed concentration (FIO2): 24%, 28%, 31%, 35%, 40%, or 50%. A non-rebreathing ("NRB") mask is designed to deliver approximately 100% oxygen. Providing 40% or more supplemental oxygen means that the doctor is treating acute respiratory failure, because only patients with acute respiratory failure need that much oxygen. A nasal cannula provides oxygen at an adjustable flow rate in liters of oxygen per minute (L / min or "LPM"). The actual FIO2 (oxygen percentage) delivered by a nasal cannula is a bit unstable and less reliable than a mask, but can be estimated as shown in the table below. The FIO2 derived from the nasal cannula flow rate can then be used to calculate the P / F ratio. Example: A patient has a pO2 of 85 mmHg on an ABG while receiving 5 L / min of oxygen. Since 5 L / min equals 40% oxygen (FIO2 of 0.40), the P / F ratio = 85 divided by 0.40 = 212.5.
[0085] In some aspects, administration of AP to a subject as disclosed herein can improve a number of parameters related to respiratory function, such as the subject's P / F ratio, oxygen saturation in arterial blood (pO2), pulse oxygen saturation (SpO2), oxygenation index, and / or respiratory index.
[0086] In some aspects, administration of an AP (e.g., RecAP) to a subject results in an increase in the P / F ratio relative to the P / F ratio of a subject without treatment. In some aspects, the P / F ratio is increased by at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190, or at least 200 mmHg relative to the P / F ratio of a subject without treatment.
[0087] In some aspects, the application of AP (e.g., RecAP) to an object increases the P / F ratio of the object relative to the baseline P / F ratio. In some aspects, the P / F ratio of the object increases by at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190, at least 200 mmHg relative to the baseline P / F ratio. In some aspects, the application of AP (e.g., RecAP) to an ARDS patient reduces the severity of ARDS from "severe" to "moderate", or from "moderate" to "mild", from "severe" to "mild", or from "moderate" or "severe" to "no ARDS", i.e. P / F>300 mmHg.
[0088] In this context, the baseline P / F ratio is defined as the P / F ratio before or around the start of treatment. The baseline P / F ratio is preferably determined on day -2, day -1, day 0 or day 1, i.e. preferably within 48 hours before the start of AP therapy and within a maximum of 24 hours after the start of AP therapy. More preferably, the baseline P / F ratio is determined within 24 hours before the start of AP therapy and within a maximum of 12 hours after the start of AP therapy, more preferably between 12 hours before the start of AP therapy and within a maximum of 6 hours after the start of AP therapy, more preferably between 12 hours before the start of AP therapy and within a maximum of the start of AP therapy, and most preferably between 6 hours before the start of AP therapy and within a maximum of the start of AP therapy. AP therapy is preferably continued until the P / F ratio is at least 200 or more, more preferably at least 300 or more, and most preferably until the subject is deemed no longer to have ARDS.
[0089] In some aspects, an increase in lung function (e.g., an increase in P / F ratio) is observed 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 days after AP administration.
[0090] In some aspects of the present disclosure, the ARDS of the subject is accompanied by or due to sepsis or viral infection. In some aspects, the ARDS of the subject is accompanied by or due to sepsis or viral infection, and AP (e.g., RecAP) is administered to the subject only when sepsis or viral infection is determined less than 96 hours before the decision to start treatment. In other aspects, the ARDS of the subject is accompanied by or due to sepsis or viral infection, and AP (e.g., RecAP) is administered to the subject only when sepsis or viral infection is determined less than 72 hours before the detection of ARDS.
[0091] In some aspects of the present disclosure, the ARDS of the subject is accompanied by or due to sepsis or a viral infection, and the subject is treated with an AP (e.g., RecAP) within 24 hours after the sepsis or viral infection is determined. The presence of sepsis can be detected, for example, by using criteria developed for determining sepsis (e.g., SIRS or SOFA). Since the first definition of "sepsis" in 1992, its definition has been re-evaluated several times, focusing on the prevailing view at the time that sepsis was caused by a systemic inflammatory response syndrome (SIRS) of the host to infection (Bone RC, Balk RA, Cerra FB, et al., American College of Chest Physicians / Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992; 20(6): 864–874). In 2001, the list of diagnostic criteria was expanded, but no alternative criteria were provided (Levy MM, Fink MP, Marshall JC, et al., International Sepsis Definitions Conference. 2001 SCCM / ESICM / ACCP / ATS / SIS International Sepsis Definitions Conference. Intensive Care Med. 2003; 29(4): 530–538). In 2016, the now widely used "Sepsis-3" criteria were recommended, which no longer use the SIRS criteria. Instead, the Sequential [Sepsis-related] Organ Failure Assessment (SOFA) is used to diagnose sepsis (Singer M, Deutschman CS, Seymour CW, et al., The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8): 801-810. doi: 10.1001 / jama.2016.0287). The STOP-AKI study described in the Examples was conducted between 2014 and 2017 and utilized SIRS and SOFA scores to identify and / or stratify patients with sepsis.For the definition and determination of "sepsis" used in this article, it is preferred to use the Sepsis-3 criteria, which are based on the SOFA score and are widely described in Singer et al. (Singer M, Deutschman CS, Seymour CW et al., The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8): 801-810. doi: 10.1001 / jama.2016.0287).
[0092] In some aspects of the disclosure, AP is administered to a subject at risk for sepsis to prevent a decrease in lung function.
[0093] In some aspects, AP treatment of the subject is initiated within 48 hours after detection of ARDS. In a preferred embodiment, AP treatment of the subject is initiated within 48 hours, preferably within 24 hours, more preferably within 12 hours, and most preferably within 6 hours after detection of moderate or severe ARDS.
[0094] In some aspects of the methods disclosed herein, administration of at least one dose of AP results in a reduction in duration or cessation of mechanical ventilation therapy in a subject undergoing mechanical ventilation therapy.
[0095] In some aspects of the methods disclosed herein, AP administration results in an increase in lung function or prevents lung function from decreasing below a critical threshold. Thus, in some aspects, AP administration can prevent lung function from decreasing below a critical threshold. Thus, in some aspects, to determine the risk of the person's lung function decreasing below a certain threshold level, an indicator of lung function (e.g., a P / F ratio) is determined prior to administering AP to preserve lung function.
[0096] In some aspects, the methods disclosed herein include detecting changes in the levels of one, two, three or more biomarkers (eg, changes in the P / F ratio), alone or in combination, to detect a marker of lung function.
[0097] In some aspects, the methods disclosed herein include predicting an increased clinical response to AP (e.g., RecAP) treatment based on a detected lung function parameter (e.g., a baseline P / F ratio). In some aspects, the methods disclosed herein include assessing whether a lung function parameter (e.g., a baseline P / F ratio) falls within a certain range, or whether it is above or below a certain threshold (e.g., a P / F ratio threshold for ARDS severity). Thus, if, for example, a lung function parameter (e.g., a baseline P / F ratio), alone or in combination with other biomarkers, indicates that the patient will benefit from AP treatment, treatment can be initiated or maintained or modified (e.g., increasing or decreasing the dose, or increasing or decreasing the dose frequency).
[0098] Conversely, if, for example, lung function parameters (e.g., baseline P / F ratio), alone or in combination with other biomarkers, indicate that the patient will not benefit from AP therapy, treatment can be interrupted, temporarily suspended, modified (e.g., increasing or decreasing the dose or increasing or decreasing the frequency of administration), etc.
[0099] In other words, specific levels of lung function parameters (e.g., baseline P / F ratio) alone or in combination with other molecular or clinical biomarkers are associated with clinical efficacy of AP therapy and can be used to predict clinical outcomes in specific populations of patients with sepsis and / or ARDS.
[0100] For some jurisdictions, the present invention provides alkaline phosphatase (AP) for use in a method of treating acute respiratory distress syndrome (ARDS) in a subject in need thereof, wherein the subject has a P / F ratio of ≤200 mmHg. Also provided is the use of alkaline phosphatase (AP) for the manufacture of a medicament for treating acute respiratory distress syndrome (ARDS) in a subject in need thereof, wherein the subject has a P / F ratio of ≤200 mmHg.
[0101] The present invention also provides alkaline phosphatase (AP) for use in a method of treating acute respiratory syndrome (ARDS) in a subject in need thereof, the method comprising administering to the subject an effective amount of alkaline phosphatase (AP), wherein (i) the subject had moderate or severe ARDS prior to treatment with AP, and (ii) administering the AP in at least one dose of 300 U / kg to 2,000 U / kg.
[0102] In moderate or severe ARDS, according to the Berlin 2012 definition, the P / F ratio is ≤200 mmHg when measured using a minimum positive end-expiratory pressure (PEEP) of 5 cmH2O.
[0103] In a preferred embodiment, the subject has moderate ARDS and has a P / F ratio of >100 and ≤200 mmHg prior to treatment with AP. In another preferred embodiment, the subject has severe ARDS and has a P / F ratio of <100 mmHg prior to treatment with AP.
[0104] In some preferred embodiments, there is provided an AP for use according to the invention or a use according to the invention, wherein the AP is a human AP.
[0105] In some preferred embodiments, the AP is a recombinant AP, preferably a chimeric AP, more preferably an AP having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to the amino acid sequence of RecAP (SEQ ID NO: 1). In some preferred embodiments, the AP is a recombinant AP having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to the amino acid sequence of RecAP (SEQ ID NO: 1), with the proviso that the amino acid at position 279 is leucine (L), the amino acid at position 328 is valine (V), and the amino acid at position 478 is leucine (L).
[0106] In a preferred embodiment, an AP for use according to the invention or a use according to the invention is provided, wherein the administration of the AP results in an increase in lung function in the subject. The increase in lung function preferably comprises an increase in the P / F ratio of the subject relative to the P / F ratio of the untreated subject.
[0107] In some preferred embodiments, an AP for use according to the invention or a use according to the invention is provided, wherein the ARDS is associated with or caused by sepsis. Preferably, sepsis is detected less than 96 hours before the administration of the AP.
[0108] In a more preferred embodiment, an AP for use according to the invention or a use according to the invention is provided, wherein the ARDS is associated with or caused by sepsis and sepsis is detected less than 72 hours before the detection of ARDS. Preferably, the AP treatment is started after the detection of sepsis and / or within 24 hours after the detection of ARDS.
[0109] In other preferred embodiments, an AP for use according to the invention or a use according to the invention is provided, wherein the ARDS is associated with or caused by a viral infection. The viral infection preferably comprises a coronavirus infection, more preferably a severe acute respiratory syndrome (SARS)-related coronavirus infection. In some preferred embodiments, the coronavirus is SARS-CoV-2.
[0110] In a preferred embodiment, an AP for use according to the invention or a use according to the invention is provided, wherein the AP is administered once a day. In a preferred embodiment, the AP is administered intravenously. In a preferred embodiment, the AP is administered in three doses per day.
[0111] In some preferred embodiments, an AP for use according to the present invention or the use according to the present invention is provided, wherein the AP is RecAP and the dosage is 0.6 mg / kg (or 375 U / kg) to 3.2 mg / kg (or 2,000 U / kg) of RecAP, preferably 0.8 mg / kg (or 500 U / kg) to 2.0 mg / kg (or 1250 U / kg), more preferably about 1.6 mg / kg (or 1000 U / kg).
[0112] Some preferred embodiments provide the AP for use according to the invention or the use according to the invention, wherein the AP is administered in at least one dose of 500 U / kg to 2,000 U / kg. Preferably, the AP dose is 500 U / kg or 1000 U / kg of RecAP. In some preferred embodiments, the AP dose is 0.8 mg / kg or 1.6 mg / kg of RecAP.
[0113] In a preferred embodiment, an AP for use according to the invention or a use according to the invention is provided, wherein the administration of at least one dose of AP results in the maintenance or increase of the P / F ratio in a subject. Preferably, the administration of at least one dose of AP results in a reduction in the duration of mechanical ventilation therapy or cessation of mechanical ventilation therapy in a subject undergoing mechanical ventilation therapy.
[0114] As used herein, the term "biomarker" refers to a factor that is a unique indicator of a biological process, biological event, and / or pathological condition, for example, a predictor of clinical response to treatment with an AP (e.g., RecAP). As used herein, the term biomarker includes clinical markers and molecular biomarkers (biomarkers). Therefore, in the context of the present disclosure, the term "biomarker" includes, for example, "biological biomarkers" or "molecular biomarkers". In some aspects, biological or molecular biomarkers for assessing lung function include inflammatory markers, such as C-reactive protein (CRP), fibrinogen, interleukin 6 (IL-6), or interleukin 8 (IL-8). More specific biomarkers associated with the diagnosis and prognosis of ARDS are receptor for advanced glycation end products (RAGE), angiopoietin-2 (Ang-2), surfactant protein D (SP-D), endothelin-8, Fas and Fas ligands, procollagen peptides of types I and III (PCP), octane, acetaldehyde, and 3-methylheptane. Typically, these are cell-specific for epithelial or endothelial damage, or are involved in inflammatory or infectious responses (García-Laorden MI, Lorente JA, Flores C, Slutsky AS, Villar J. Biomarkers for the acute respiratory distress syndrome: how to make the diagnosis more precise. Ann Transl Med. 2017; 5(14): 283).
[0115] As disclosed above, the term "biomarker" also includes "clinical biomarkers," also known as "clinical status markers," which can predict response to biological therapy, for example, sex, age, concomitant medications, smoking status, body mass index (BMI), etc.
[0116] As discussed above, a critical approach based on baseline P / F values is applied to classify ARDS as "severe ARDS" or "moderate ARDS". For example, differences in P / F levels observed in subjects with "severe ARDS", "moderate to severe ARDS", or "mild ARDS" can be applied to predict clinical outcomes when treating patients with an AP (e.g., RecAP). Thus, if a subject's P / F ratio is below a certain threshold (e.g., 200 mmHg), the subject will become a candidate for treatment with a certain AP therapy, for example, treatment with a certain AP regimen comprising one or more doses of RecAP.
[0117] In some aspects, merely determining that the P / F ratio is below a predetermined threshold level is sufficient to identify a subject as a candidate for treatment with a certain AP therapy (e.g., with RecAP therapy). Thus, in some aspects of the methods disclosed herein, the P / F ratio can be used alone. However, in other aspects, the P / F ratio can be combined with other measures of lung function (e.g., using spirometry) and / or molecular or clinical biomarkers, such as, for example, markers selected from the following: C-reactive protein (CRP), fibrinogen, interleukin 6 (IL-6) or interleukin 8 (IL-8), receptor for advanced glycation end products (RAGE), angiopoietin-2 (Ang-2), surfactant protein D (SP-D), endothelin-8, Fas and Fas ligands, procollagen peptides type I and III (PCP), octane, acetaldehyde, and 3-methylheptane.
[0118] These findings can be applied, for example, to design new methods of determining treatment (e.g., by selecting patients as candidates for a particular AP treatment), methods of treating decline in lung function, preventing decline in lung function, increasing lung function, or preserving lung function (e.g., to treat ARDS), methods of monitoring the efficacy of AP treatment, or methods of adjusting formulations, dosage regimens, or routes of administration.
[0119] The methods disclosed herein include prescribing, initiating and / or altering prophylaxis and / or treatment based on the severity of ARDS as typically categorized based on the subject's P / F ratio (as described above), alone or in combination with one or more additional biomarkers.
[0120] The present disclosure provides a method for determining whether to treat a patient suffering from ARDS with a treatment regimen comprising administration of an AP, wherein the method comprises: (a) determining a P / F ratio (or another lung function parameter), and optionally measuring or instructing a clinical laboratory to measure the level of an additional biomarker in a sample taken from the patient, such as, for example, C-reactive protein (CRP), fibrinogen, interleukin 6 (IL-6) or interleukin 8 (IL-8), receptor for advanced glycation end products (RAGE), angiopoietin-2 (Ang-2), surfactant protein D (SP-D), interleukin-8, Fas and Fas ligand, procollagen peptides type I and III (PCP), octane, acetaldehyde and / or 3-methylheptane, and (b) if the patient is determined to have a higher or lower P / F ratio compared to a predetermined threshold level, and / or compared to the P / F ratio or another lung function parameter in a control, or another lung function parameter), and optionally, a higher or lower level of additional biomarkers in the sample, such as, for example, C-reactive protein (CRP), fibrinogen, interleukin 6 (IL-6) or interleukin 8 (IL-8), receptor for advanced glycation end products (RAGE), angiopoietin-2 (Ang-2), surfactant protein D (SP-D), interleukin-8, Fas and Fas ligand, type I and III procollagen peptides (PCP), octane, acetaldehyde, and / or 3-methylheptane, compared to one or more predetermined threshold levels for each biomarker, or compared to one or more levels of each biomarker in one or more controls, then treat or instruct a healthcare provider to treat the patient with a treatment regimen that includes administering an AP (e.g., RecAP), or to withhold treatment, not initiate treatment, refuse treatment, or instruct a healthcare provider to withhold, not initiate, or refuse treatment.
[0121] In one aspect, the present disclosure provides a method for determining whether to treat a patient suffering from ARDS with a treatment regimen comprising administration of an AP, wherein the method comprises: (a) determining the P / F ratio (or another lung function parameter), and optionally measuring or instructing a clinical laboratory to measure the level of an additional biomarker in a sample taken from the patient, such as, for example, C-reactive protein (CRP), fibrinogen, interleukin 6 (IL-6) or interleukin 8 (IL-8), receptor for advanced glycation end products (RAGE), angiopoietin-2 (Ang-2), surfactant protein D (SP-D), interleukin-8, Fas and Fas ligand, Type I and III procollagen peptides (PCP), octane, acetaldehyde and / or 3-methylheptane, and (b) if the patient is determined to have a lower or decreased P / F ratio (or another lung function parameter) compared to a predetermined threshold level, and / or compared to the P / F ratio or another lung function parameter in a control, and optionally a higher or lower level of at least one optional additional biomarker in the sample compared to one or more threshold levels of predetermined biomarkers, or compared to one or more levels of the biomarkers in one or more controls, then treat or instruct a healthcare provider to treat the patient with a treatment regimen comprising administration of AP.
[0122] In one aspect, the present disclosure provides a method for determining whether to treat a patient suffering from ARDS with a treatment regimen comprising administration of an AP, wherein the method comprises: (a) determining a P / F ratio (or another lung function parameter), and optionally measuring or instructing a clinical laboratory to measure the level of an additional biomarker in a sample taken from the patient, such as, for example, C-reactive protein (CRP), fibrinogen, interleukin 6 (IL-6) or interleukin 8 (IL-8), receptor for advanced glycation end products (RAGE), angiopoietin-2 (Ang-2), surfactant protein D (SP-D), interleukin-8, Fas and Fas ligand, procollagen peptides type I and III (PCP), octane, acetaldehyde and / or 3-methylheptane, and (b) withholding treatment with a treatment regimen comprising administering an AP (e.g., RecAP) to the patient, not initiating treatment, refusing treatment, or instructing a healthcare provider to withhold, not initiate, or refuse to treat the patient with a treatment regimen comprising administering an AP (e.g., RecAP) to the patient if the patient is determined to have a higher or increased P / F ratio (or another lung function parameter) as compared to a predetermined threshold level, and / or as compared to the P / F ratio or another lung function parameter in a control, and optionally a higher or lower level of at least one optional additional biomarker in the sample as compared to one or more threshold levels of the biomarker as predetermined, or as compared to one or more levels of the biomarker in one or more controls.
[0123] Also provided are methods of selecting a patient diagnosed with ARDS as a candidate for treatment with an AP, comprising: (a) determining the P / F ratio (or another lung function parameter), and optionally measuring or instructing a clinical laboratory to measure the level of an additional biomarker in a sample taken from the patient, such as, for example, C-reactive protein (CRP), fibrinogen, interleukin 6 (IL-6) or interleukin 8 (IL-8), receptor for advanced glycation end products (RAGE), angiopoietin-2 (Ang-2), surfactant protein D (SP-D), interleukin-8, Fas and Fas ligands; body, type I and III procollagen peptides (PCP), octane, acetaldehyde and / or 3-methylheptane, and (b) if the patient is determined to have a lower or decreased P / F ratio (or another lung function parameter) compared to a predetermined threshold level, and / or compared to the P / F ratio or another lung function parameter in a control, and optionally a higher or lower level of at least one optional additional biomarker in the sample compared to a predetermined one or more threshold levels, or compared to one or more levels of the biomarker in one or more controls, then treat or instruct a healthcare provider to treat the patient with AP.
[0124] Also provided are methods for selecting a patient diagnosed with ARDS as a candidate for treatment with an AP, comprising: (a) determining the P / F ratio (or another lung function parameter), and optionally measuring or instructing a clinical laboratory to measure the level of an additional biomarker in a sample taken from the patient, such as, for example, C-reactive protein (CRP), fibrinogen, interleukin 6 (IL-6) or interleukin 8 (IL-8), receptor for advanced glycation end products (RAGE), angiopoietin-2 (Ang-2), surfactant protein D (SP-D), interleukin-8, Fas and Fas ligand, procollagen type I and III peptides (PCP), octane, acetaldehyde, and / or 3-methylheptane, and (b) withholding treatment with the AP (e.g., RecAP) for the patient, not initiating treatment, refusing treatment, or instructing a healthcare provider to withhold, not initiate, or refuse treatment with the AP (e.g., RecAP) for the patient if the patient is determined to have a higher or increased P / F ratio (or another lung function parameter) compared to a predetermined threshold level, and / or compared to the P / F ratio or another lung function parameter in a control, and optionally a lower or decreased level of at least one optional additional biomarker in the sample compared to a predetermined one or more threshold levels, or compared to one or more levels of the biomarker in one or more controls.
[0125] In some aspects, the disclosed methods may require ordering and / or performing one or more additional assays. For example, a P / F ratio (or another lung function parameter) determination assay may be repeated to exclude false negative results, and / or one or more additional P / F ratio (or another lung function parameter) determination assays may be performed to monitor the subject's status. Conversely, a P / F ratio (or another lung function parameter) determination assay may need to be repeated to exclude false positive results.
[0126] In some aspects, the presence of a P / F ratio (or another lung function parameter) above or below a predetermined threshold level in a patient with ARDS can be used in combination with one or more clinical or molecular biomarkers specific for sepsis, or for specific infections leading to sepsis in a patient with ARDS associated with or caused by sepsis.
[0127] One skilled in the art will appreciate that the P / F ratio (or another lung function parameter) can be used in accordance with the methods disclosed herein, including but not limited to therapeutic, diagnostic, and monitoring methods, as a positive selector, i.e., if the patient's P / F ratio (or another lung function parameter) is below or above a predetermined P / F ratio (or another lung function parameter) threshold level, or if the P / F ratio (or another lung function parameter) is increased or decreased relative to the P / F ratio (or another lung function parameter) in one or more controls, a specific action will be taken (e.g., treating the patient).
[0128] Those skilled in the art will appreciate that the P / F ratio (or another lung function parameter) can be used in accordance with the methods disclosed herein, including but not limited to therapeutic, diagnostic and monitoring methods, as a negative selector, i.e., if the patient's P / F ratio (or another lung function parameter) is below or above a predetermined P / F ratio (or another lung function parameter) threshold level, or if the P / F ratio (or another lung function parameter) is increased or decreased relative to the P / F ratio (or another lung function parameter) in one or more controls, a specific action will be taken (e.g., treating the patient).
[0129] In one aspect, the present disclosure includes methods of facilitating a determination by a healthcare provider, healthcare benefit provider, or clinical laboratory as to whether a patient would benefit from AP treatment.
[0130] On the one hand, the methods disclosed herein include diagnosing based at least in part on the P / F ratio (or another pulmonary function parameter) of the patient, which diagnosis can be a differential diagnosis. In some aspects, the methods disclosed herein include notifying the subject of the P / F ratio (or another pulmonary function parameter) to determine the results of the determination and / or diagnosis based at least in part on the P / F ratio (or another pulmonary function parameter). The patient can be notified verbally, in writing and / or electronically. The diagnosis can also be recorded in the patient's medical record.
[0131] The term "medical record" or "patient medical record" refers to an account of a patient's examination and / or treatment, which typically includes one or more of the following: the patient's medical history and complaints, the physician's physical examination results, the results of diagnostic tests and procedures, and the patient's medications and treatment procedures. A medical record is typically made by one or more physicians and / or physician assistants, and is a written, transcribed, or otherwise recorded record and / or history of various illnesses or injuries requiring medical care and / or vaccinations, and / or allergies, and / or treatments, and / or prognosis, and / or often health information about parents, siblings, and / or occupations. A physician may review the record when diagnosing a condition.
[0132] Medical records can be in paper form and / or can be stored in a computer-readable medium. Medical records can be maintained by a laboratory, a doctor's office, a hospital, a health care maintenance organization, an insurance company, and / or a personal medical record website. In some aspects, a diagnosis based at least in part on the determined P / F ratio is recorded on or in a medical alert item such as a card, a wearable item, and / or a radio frequency identification (RFID) tag. As used herein, the term "wearable item" refers to any item that can be worn on a subject's body, including but not limited to a tag, a bracelet, a necklace, an armband, or a headband.
[0133] As used herein, the term "diagnosis" means detecting a disease or determining the stage or extent of a disease. Typically, the diagnosis of a disease is based on the evaluation of one or more factors and / or symptoms indicating the disease. That is, the diagnosis can be made based on the presence, absence or amount of factors indicating the presence or absence of a disease or condition. Each factor or symptom considered to indicate a diagnosis of a specific disease does not need to be uniquely associated with the specific disease, for example, there may be a differential diagnosis that can be inferred from the diagnostic factors or symptoms. Similarly, there may be a situation where factors or symptoms indicating a specific disease are present in individuals who do not suffer from the specific disease.
[0134] The term "diagnosis" also includes determining the therapeutic effect of drug therapy (e.g., AP therapy), or predicting the response pattern to drug therapy. Diagnostic methods can be used independently or in combination with other diagnostic and / or staging methods known in the medical art for a particular disease.
[0135] As used herein, the term "differential diagnosis" refers to determining which of two or more diseases with similar symptoms may be causing a subject's symptoms based on analysis of clinical data. The term is also used to refer to determining whether a patient is susceptible to AP treatment, depending on whether the patient's determined P / F ratio (or another lung function parameter) is above or below a predetermined threshold level, or is elevated or depressed relative to one or more control levels.
[0136] As used herein, the term "prognosis" refers to a prediction of the possible course and outcome of a clinical condition or disease (e.g., sepsis or ARDS). Prognosis is usually made by evaluating factors or symptoms of the disease, which indicate a favorable or unfavorable course or outcome of the disease. As used herein, the phrase "determining the prognosis" refers to a process by which a person skilled in the art is able to predict the course or outcome of a patient's condition. The term "prognosis" does not refer to the ability to predict the course or outcome of a condition with 100% accuracy. On the contrary, the technician will understand that the term "prognosis" refers to an increased probability that a certain process or outcome will occur; that is, a process or outcome is more likely to occur in a patient showing a given condition when compared to those individuals who do not show the condition.
[0137] As used herein, the terms "good prognosis" and "positive prognosis" or "poor prognosis" and "negative prognosis" are relative terms used to predict the likely course and / or likely outcome of a condition or disease (e.g., sepsis or ARDS). A good or positive prognosis predicts a better outcome for a condition than a poor or negative prognosis. In a general sense, a "good prognosis" is an outcome that is relatively better than many other possible prognoses that may be associated with a particular condition, while a poor prognosis predicts an outcome that is relatively worse than many other possible prognoses that may be associated with a particular condition. Typical examples of a good or positive prognosis include increased lung function, preserved lung function, an increase in the P / F ratio (or another lung function parameter), etc.
[0138] The present disclosure includes methods of treating ARDS in a subject, or APs for use in methods of treating ARDS in a subject, based on changes in expression of the P / F ratio (or another lung function parameter). The present disclosure provides methods of treating a patient suffering from ARDS, or APs for use in methods of treating ARDS in a patient, wherein the method comprises administering an AP to the patient if the patient is determined to have a lower or decreased P / F ratio (or another lung function parameter) compared to a predetermined P / F ratio (or another lung function parameter) threshold level, or compared to the P / F ratio (or another lung function parameter) in one or more controls.
[0139] The present disclosure also provides a method of treating a patient suffering from ARDS, or an AP for use in a method of treating ARDS in a patient, wherein the method comprises: (a) measuring pO2 and FiO2 (or deriving pO2 and FiO2 from another measurable lung function parameter) and determining a P / F ratio (or another lung function parameter), and (b) administering the AP to the patient if the patient has a lower or decreased P / F ratio (or another lung function parameter) compared to a predetermined P / F ratio (or another lung function parameter) threshold level, or compared to the level of the P / F ratio (or another lung function parameter) in one or more controls.
[0140] Also provided is a method of treating a patient suffering from ARDS, or an AP for use in a method of treating ARDS in a patient, wherein the method comprises: (a) determining a P / F ratio (or another lung function parameter) in the patient, and (b) suspending or not initiating administration of an AP (e.g., RecAP) to the patient if the patient has a higher or increased P / F ratio (or another lung function parameter) compared to a predetermined P / F ratio (or another lung function parameter) threshold level, or compared to the level of the P / F ratio (or another lung function parameter) in one or more controls.
[0141] The present disclosure also provides a method of treating a patient suffering from ARDS, or an AP in a method for treating ARDS in a patient, wherein the method comprises: (a) measuring the patient's pO2 and FiO2 (or deriving pO2 and FiO2 from another measurable lung function parameter) and determining a P / F ratio (or another lung function parameter), and (b) determining whether the P / F ratio (or another lung function parameter) is higher or increased, or lower or decreased, compared to a predetermined P / F ratio (or another lung function parameter) threshold level. In some aspects, the method further includes administering an AP (e.g., RecAP) to the patient or recommending to a healthcare provider that an AP (e.g., RecAP) be administered to the patient if the patient is determined to have a lower or decreased P / F ratio (or another lung function parameter) compared to a predetermined P / F ratio (or another lung function parameter) threshold level, or compared to the P / F ratio (or another lung function parameter) level in one or more controls; or withholding or withholding administration of the AP if the patient is determined to have a higher or increased P / F ratio (or another lung function parameter) compared to a predetermined P / F ratio (or another lung function parameter) threshold level, or compared to the P / F ratio (or another lung function parameter) level in one or more controls.
[0142] Also provided is a method of treating a patient suffering from ARDS, or an AP for use in a method of treating ARDS in a patient, wherein the method comprises: (a) measuring the patient's pO2 and FiO2 (or deriving pO2 and FiO2 from another measurable lung function parameter) and determining a P / F ratio (or another lung function parameter), and (b) administering AP to the patient if the patient is determined to have a lower or decreased P / F ratio (or another lung function parameter) compared to a predetermined P / F ratio (or another lung function parameter) threshold level, or compared to the P / F ratio (or another lung function parameter) level in one or more controls; or withholding, not initiating, or refusing administration of AP to the patient if the patient is determined to have a higher or increased P / F ratio (or another lung function parameter) compared to a predetermined P / F ratio (or another lung function parameter) threshold level, or compared to the P / F ratio (or another lung function parameter) level in one or more controls.
[0143] The present disclosure also provides a method for measuring the efficacy or pharmacodynamics of an AP in a patient diagnosed with ARDS, comprising: (a) making a first determination of the patient's P / F ratio (or another lung function parameter); (b) administering an AP (e.g., RecAP); and (c) making a second determination of the patient's P / F ratio (or another lung function parameter), wherein an increase in the P / F ratio (or another lung function parameter) in the second determination compared to the patient's P / F ratio (or another lung function parameter) in the first determination indicates that the patient has responded to treatment with the AP (e.g., RecAP).
[0144] The present disclosure also provides a method for measuring the efficacy or pharmacodynamics of an AP in a patient diagnosed with ARDS, comprising: (a) making a first determination of the patient's P / F ratio (or another lung function parameter); (b) administering an AP (e.g., RecAP); and (c) making a second determination of the patient's P / F ratio (or another lung function parameter), wherein a decrease in the P / F ratio (or another lung function parameter) in the second determination compared to the patient's P / F ratio (or another lung function parameter) in the first determination indicates that the patient is not responding to treatment with the AP (e.g., RecAP).
[0145] In some aspects, the second determination is made 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 days after administration of an AP (e.g., RecAP), or at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 weeks, or at times therebetween.
[0146] In certain aspects, in all treatment methods disclosed herein, a "loading" dose of AP is administered to achieve a patient's desired level of lung function. If the AP loading dose does not significantly affect the patient's lung function, then a decision can be made to discontinue treatment—e.g., to switch to an alternative therapy.
[0147] If the loading dose results in an increase in the patient's lung function, then a decision may be made to reduce the AP dose size or frequency to a "maintenance" dose. It is important to note that the methods provided herein are guidelines for healthcare providers to administer treatment, and that the ultimate treatment decision will be based on the healthcare provider's sound judgment.
[0148] According to the methods disclosed herein, the formulation, dosage regimen, and route of administration of the AP (e.g., RecAP) can be adjusted to provide an effective amount for optimal therapeutic response. With respect to the administration of the AP, the AP can be administered by any suitable means, composition, and route known in the art. With respect to the dose bolus, it can be administered as a single bolus, it can be administered in several portions over time, or the dose can be proportionally reduced or increased as indicated by the urgency of the therapeutic situation. III. Alkaline phosphatase (AP)
[0149] Alkaline phosphatase (AP; EC 3.1.3.1 according to the IUBMB enzyme nomenclature) is an enzyme that catalyzes the reaction of phosphatase monoesters and H2O to alcohol and phosphate. Other names for AP are alkaline phosphomonoesterase; phosphomonoesterase; glycerophosphatase; alkaline phosphatase; alkaline phenylphosphatase; orthophosphate monoester phosphohydrolase (optimally alkaline). The systematic name for AP is phosphomonoester phosphohydrolase (optimally alkaline).
[0150] AP is a broadly specific enzyme that also catalyzes transphosphorylation. In humans and other mammals, at least four different but related APs are known. They are intestinal, placental, placental-like, and liver / bone / kidney (or tissue-nonspecific) APs. The first three are located together on chromosome 2, while the tissue-nonspecific form is located on chromosome 1.
[0151] The term "AP of the present disclosure" refers to isolated alkaline phosphatase, including its splice variants, isoforms and polymorphic forms. Recombinant AP and chimeric AP are also included. In a specific aspect, the AP is RecAP. The amino acid sequence of RecAP is shown in Figure 2 In some aspects, the AP used herein has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1. In some aspects, the AP is a functional fragment (i.e., a fragment of the AP, e.g., an AP that retains at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% of the AP activity of the corresponding full-length AP). In some aspects, the AP is a variant or derivative of the AP disclosed herein.
[0152] The AP for use according to the present disclosure may be a commercial AP enzyme, or any composition comprising an AP enzyme and any means capable of producing a functional AP enzyme in the context of the present invention, such as a DNA or RNA nucleic acid encoding an AP protein.
[0153] Nucleic acids encoding APs can be embedded in suitable vectors, such as plasmids, phagemids, phages, (retro) viruses, transposons, gene therapy vectors and other vectors capable of inducing or conferring AP production. In the context of the present disclosure, natural or recombinant microorganisms (such as bacteria, fungi, protozoa and yeast) can also be used as sources of APs.
[0154] The AP-containing composition for use according to the present disclosure may comprise eukaryotic APs (e.g., mammalian APs), which may be tissue-nonspecific AP types (e.g., liver-bone or kidney types), or tissue-specific APs (e.g., placental APs, intestinal APs, and placental-like APs). The latter are also known as germ cell APs, which are localized in the testis, thymus, and certain germ cell tumors, and are closely related to both placental and intestinal forms of APs.
[0155] In some aspects, the mammalian AP is a human or bovine AP. Non-limiting examples of human AP sequences can be found in the NCBI (Genpept) collection and include: NP_001622 (intestinal AP), NP_001623 (placental AP), NP_112603 (placental-like AP), or NP_000469 (tissue non-specific AP). In some aspects, the AP includes a polymorphic form. In some aspects, the AP is a placental AP, a placental-like AP, an intestinal AP, a liver / bone / kidney AP, or a combination thereof. In some aspects, the AP is a recombinant AP.
[0156] From a conformational point of view, AP is roughly composed of two domains: the crown domain and the active site domain. The active site domain can be divided into different parts, such as the catalytic residues and the three metal ion sites (Zn1, Zn2 and Mg3). From a primary structure point of view, the crown domain is flanked by amino acids that form the active site domain. The amino acid sequence of AP and the relative positions of the catalytic domain and the crown domain are known to the skilled person.
[0157] In some aspects of the present disclosure, the AP is an isolated or recombinant AP comprising a crown domain and a catalytic domain, wherein the crown domain and the catalytic domain are obtained from different APs, and wherein at least one of the different phosphatases is a human phosphatase. In some aspects, the AP is, for example, an ECAP (Escherichia coli AP) or one of the seven known BIAPs (bovine intestinal APs).
[0158] In some aspects, the AP is an isolated or recombinant AP comprising a crown domain and a catalytic domain, wherein the crown domain and the catalytic domain are obtained from different APs, and wherein the different AP is a human AP. This is particularly useful if the modified phosphatase is subsequently used in human therapy. The AP used in the disclosed methods can be modified, for example, a genetically modified human-derived AP that is non-immunogenic or only weakly immunogenic.
[0159] The modified AP disclosed herein can be used, for example, for "in vitro" or "ex vivo" diagnosis or therapy. Such modified phosphatases can include, for example, human and E. coli AP, or can consist of bovine and E. coli AP.
[0160] In some aspects of the present disclosure, the AP is an isolated or recombinant AP comprising a crown domain and a catalytic domain, wherein the crown domain and the catalytic domain are obtained from different APs, and wherein the crown domain is the crown domain of a placental AP (ALPP), and wherein the catalytic domain is the catalytic domain of an intestinal AP (ALPI). In some aspects, at least one of the different APs is a human phosphatase. In other aspects, both different APs are human phosphatases.
[0161] Table 1 lists domain swap mutants suitable for use in the human AP-based methods disclosed herein.
[0162] Table 1 Domain-swapped alkaline phosphatases. ALPI is the intestinal AP, ALPP is the placental AP, GCAP is the placental-like (or germ cell) AP, and TNAP is the tissue-nonspecific AP. Catalytic domain Crown domain called ALPI GCAP catALPI / Coronary GCAP TNAP catALPI / Coronary TNAP ALPP catALPI / coronary ALPP ALPP GCAP catALPP / coronary GCAP TNAP catALPP / Coronary TNAP ALPI catALPP / coronary ALPI GCAP ALPI catGCAP / Coronary ALPI ALPP catGCAP / coronary ALPP TNAP catGCAP / Coronary TNAP TNAP ALPI catTNAP / coronary ALPI ALPP catTNAP / coronary ALPP GCAP catTNAP / coronary GCAP
[0163] In some aspects, the AP is a combination of the catalytic domain of ECAP or any human form (ALPI, ALPP, GCAP or TNAP) and the coronal domain of BIAP. In addition, a combination of the catalytic domain of BIAP and the coronal domain of any human form can also be produced.
[0164] In some aspects, the modified AP is an AP that is naturally attached to the cell membrane via a glycosylphosphatidylinositol (GPI) anchor, but is modified so that it is no longer attached to the cell membrane. All isozymes are functionally active in the cell membrane, and defective forms of the GPI anchor do not exist naturally at detectable levels. Although serum AP activity has been demonstrated, it is generally believed that the enzyme is still present in shed membrane fractions or membrane vesicles. AP activity in milk is also present in fractions containing membrane vesicles. The GPI anchor is stored in the cell as a precursor molecule, where it is attached to the attachment site by a transamidase. The backbone of the GPI anchor is the same in mammals, but cell type-dependent modifications are known.
[0165] In some aspects, for treatment of human subjects, the AP is human. This is preferred due to the fact that forms of the AP obtained from other species may be immunogenic in human subjects and treatment may elicit immune responses and pathological side effects. In some subjects, even fatal side effects (i.e., anaphylactic shock) may occur, and therefore, it is preferred to minimize the risk of immunological side effects by using human forms of the AP.
[0166] Since it is not feasible to isolate AP from humans, human recombinant forms of AP proteins can be routinely produced in different recombinant expression platforms. However, expression and purification of GPI-modified and membrane-anchored proteins are notoriously difficult; GPI proteins are difficult to separate from membranes and are difficult to isolate and purify. Therefore, in some aspects, the recombinant Ap comprises a modification in the GPI signal sequence, wherein the modification results in a secreted AP, i.e., the AP is not attached to the cell membrane.
[0167] There is no universal sequence responsible for the attachment of the GPI anchor, but there are some specific shared features: (i) a hydrophobic stretch of amino acids at the C-terminus (at least 11 amino acids, but preferably more than 11 amino acids); (ii) upstream of the hydrophobic region, a spacer of hydrophilic amino acids (5–12 amino acids); (iii) GPI-linked to a small amino acid: glycine, aspartic acid, asparagine, alanine, serine, or cysteine; and (iv) The two subsequent amino acids downstream of the GPI attachment site must be small amino acids, and in most cases they are selected from: glycine, aspartic acid, asparagine, alanine, serine or cysteine.
[0168] In some aspects, the recombinant AP comprises a modification in the GPI signal sequence, wherein the modification produces a secreted AP that is biologically active, i.e., it exhibits activity on biologically relevant substrates. In some aspects, the secreted AP is human AP. In some aspects, the secreted human AP is human liver-kidney-bone phosphatase, human intestinal AP, or human placental alkaline phosphatase.
[0169] Based on the above common features, a skilled person can introduce modifications, for example, by inserting one or more amino acids, which will disrupt the common part and will result in the inability of the AP to be linked to the GPI anchor. Thus, in some aspects, the recombinant AP comprises a modification in the GPI signal sequence, which produces a secreted AP, wherein the modification comprises a mutation or deletion of at least one amino acid in the sequence comprising the common GPI signal sequence.
[0170] In some aspects, the AP is an AP disclosed in U.S. Pat. No. 8,557,545. In some aspects, the AP is a chimeric AP or a chimeric AP-like protein, such as those described in U.S. Patent Application Publications No. US2017 / 0009216 and US2014 / 0193388. Preferably, the AP is a recombinant alkaline phosphatase comprising the catalytic domain of ALPI (intestinal alkaline phosphatase) and the crown domain of ALPP (placental alkaline phosphatase). More preferably, the AP is RecAP (corresponding to SEQ ID NO: 1, and described in U.S. Patent Application Publication No. US2017 / 0009216).
[0171] In some aspects, the APs of the present disclosure comprise (i) a sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least 99% sequence identity to the crown domain of human ALPP, and (ii) a sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least 99% sequence identity to the catalytic domain of human ALPI.
[0172] In some aspects, the sequence having the sequence identity to the corona domain of ALPP is located in a protein according to the invention at approximately the same position as the corona domain of ALPP in a native ALPP protein.
[0173] The percent identity of an amino acid or nucleic acid sequence, or the term "% sequence identity", is defined herein as the percentage of residues in the candidate amino acid or nucleic acid sequence that are identical to the residues in the reference sequence after aligning the residues in the candidate amino acid or nucleic acid sequence with the residues in the reference sequence and introducing gaps, if necessary, to achieve the maximum percent identity. In a preferred embodiment, the calculation of the percent sequence identity is performed without introducing gaps. Methods and computer programs for alignment are well known in the art, such as "Align 2" or the BLAST service of the National Center for Biotechnology Information (NCBI).
[0174] In some embodiments, the present invention provides alkaline phosphatase (AP) for use in a method of treating acute respiratory distress syndrome (ARDS) in a subject in need thereof, the method comprising administering an effective amount of alkaline phosphatase (AP) to the subject, wherein the subject suffers from moderate or severe ARDS prior to treatment with AP, and AP administration results in an increase in respiratory function. In a preferred embodiment, the subject suffers from severe ARDS prior to treatment with AP. In another preferred embodiment, the subject suffers from moderate ARDS prior to treatment with AP.
[0175] In some preferred embodiments, AP is administered in at least one dose of 500 U / kg to 2,000 U / kg. Preferably, ARDS is associated with or caused by sepsis, or ARDS is associated with or caused by a viral infection. In the case where ARDS is associated with or caused by sepsis, sepsis is preferably detected within less than 96 hours prior to AP administration, more preferably within less than 72 hours prior to ARDS detection. Preferably, treatment is initiated within 24 hours after detection of sepsis.
[0176] In some preferred embodiments, the AP is a human AP, and / or the AP is a recombinant AP. If the AP is recombinant, it is preferably a chimeric AP. Preferably, the chimeric AP has at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence of RecAP (SEQ ID NO: 1).
[0177] In some preferred embodiments, an AP for use according to the present invention is provided, wherein the increase in respiratory function comprises an increase in the P / F ratio relative to the P / F ratio without treatment with the AP.
[0178] In some preferred embodiments, there is provided an AP for use according to the present invention, wherein the treatment is initiated within 24 hours after detection of ARDS.
[0179] In some preferred embodiments, the AP is administered once daily and / or intravenously. Preferably, the AP is administered in three doses per day. Preferably, each AP dose is about 0.8 mg / kg or about 1.6 mg / kg of RecAP, and / or the AP dose is about 500 U / kg or about 1000 U / kg of RecAP. In this context, "about" means + / - 20%, preferably + / - 10%, most preferably + / - 5% of the indicated dose. For an average individual (e.g., an individual weighing about 60-80 kg, the dosage per dose will be about 30,000 U - about 160,000 U, preferably about 30,000 U to about 80,000 U, more preferably about 60,000 U to about 80,000 U. The dosage expressed in mg will be equivalent to about 48 mg to about 256 mg, preferably 48 mg to about 128 mg, more preferably 96-128 mg. Therefore, there is also provided an AP for use according to the present invention, wherein the dosage is about 30,000 U to about 160,000 U, preferably about 30,000 U to about 80,000 U, more preferably about 60,000 U to about 80,000 U. There is also provided an AP for use according to the present invention, wherein the dosage is about 48 mg to about 256 mg, preferably 48 mg to about 128 mg, more preferably 96-128 mg.
[0180] In some preferred embodiments, an AP for use according to the present invention is provided, wherein administration of at least one dose of the AP results in a reduction in the duration of or cessation of mechanical ventilation therapy in a subject undergoing mechanical ventilation therapy.
[0181] Preferably, administration of at least one dose of the AP results in the maintenance or increase of the P / F ratio in the subject. More specifically, the AP for use according to the invention results in a reduction in the risk of death in the subject. Treatment of one or more subjects who are part of a group of subjects suffering from moderate or acute acute respiratory distress syndrome will result in a reduction in the mortality rate of said group of subjects.
[0182] Although the present application may describe features as part of the same embodiment or as part of separate embodiments, the scope of the invention also includes embodiments including any combination of all or some of the features described herein.
[0183] The present invention is further explained in the following examples. These examples do not limit the scope of the present invention, but are only used to illustrate the present invention. Example Example 1 Human recombinant alkaline phosphatase for acute respiratory distress syndrome
[0184] Acute respiratory distress syndrome (ARDS) adversely affects long-term pulmonary outcomes and survival. In preclinical studies, administration of the detoxifying enzyme alkaline phosphatase improves lung inflammatory parameters. We investigated the role of human recombinant alkaline phosphatase (RecAP) ( Figure 2 ) in patients with ARDS.
[0185] In part 1 of the adaptive phase 2a / 2b STOP-AKI trial, patients were randomized to receive RecAP 0.4, 0.8, or 1.6 mg / kg or placebo once daily for 3 days to determine the optimal dose.
[0186] In part 2, this dose was compared with placebo. The primary endpoint was the time-adjusted area under the curve (AUC) for endogenous creatinine clearance from days 1 to 7. 1-7 ECC), with renal replacement therapy (RRT) as a key secondary endpoint. Pulmonary function was also analyzed. A total of 301 patients were enrolled. No differences in (serious) adverse events between RecAP and placebo were observed between the groups. RecAP appears to be safe and well tolerated. method
[0187] STOP-AKI Trial Design and Participants
[0188] The STOP-AKI trial is an international, randomized, double-blind, placebo-controlled, four-arm, parallel-group, dose-finding adaptation phase 2a / 2b trial in critically ill adults with sepsis-associated acute kidney injury. The protocol and primary results of the STOP-AKI study have been published previously (Pickkers P, Mehta RL, Murray PT, et al., Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury: A Randomized Clinical Trial. JAMA. 2018; 320(19): 1998-2009).
[0189] ICU patients aged ≥18 years with a diagnosis of sepsis (Levy et al., Crit Care Med 2003;31:1250-6) and a first diagnosis of AKI (Mehta et al., Crit Care 2007;11:R31) were eligible for the study. Inclusion and exclusion criteria and primary outcomes are described in Pickkers et al. (JAMA 2018).
[0190] Outcome measures
[0191] The main aim of this study was to investigate the optimal therapeutic dose of RecAP and to assess its effect on kidney function. Effects on other organs, such as the lungs, were also investigated.
[0192] Safety, tolerability, pharmacokinetics (in the first 120 patients), immunogenicity, systemic and urinary biomarkers, and the effect of RecAP on quality of life and other non-renal parameters in patients with SA-AKI were also investigated. Lung function analyses are described in detail below. Arterial oxygen partial pressure (PaO2) / inspired oxygen fraction (FiO2) in mechanically ventilated patients Lung function was assessed by (P / F ratio), Carrico index, positive end-expiratory pressure (PEEP), and tidal volume. Ventilation-free days: The number of days alive and independent of mechanical ventilation from randomization to day 28 (inclusive). A ventilation-free day is defined as a day on which the patient does not use ventilation (invasive or non-invasive mechanical ventilation). • Ventilated Days: For those patients on mechanical ventilation at the start of the period, the number of days from the first administration of study drug to the discontinuation of mechanical ventilation (from Day 1 to Day 28, inclusive).
[0193] Statistical analysis
[0194] Data were analyzed based on the intention-to-treat principle for patients who had given informed consent and were randomly assigned to treatment groups. Details related to sample size calculation are described below.
[0195] Sample size calculation
[0196] In part 1, the planned sample size was n1 = 30 patients per treatment group, and in part 2, an additional n2 = 85 patients were recruited to the optimal RecAP dose group and the placebo treatment group (total sample size of n = 290 patients). Custom programming simulations were performed using SAS software V.9.2 to determine the power and type I error rate of the selected sample size and design in a number of different dose-response scenarios. Each scenario assumed a standard deviation of 49 ml / min for the primary endpoint, an assumed response of 60 ml / min in the placebo group, and RecAP dose groups between 60 ml / min (no treatment effect) and 79 ml / min (strong treatment effect).
[0197] Fifty thousand simulations were performed to show a one-sided type I error rate of 2.4% (and therefore well controlled at a one-sided 2.5% significance level). Power was defined as the probability of rejecting the null hypothesis (no difference between treatment groups) when one or more of the RecAP dose groups had a treatment effect, defined as a response of 69.5 ml / min. This was studied in seven scenarios, with 10 000 simulations performed for each scenario. The chosen design achieved a power of 79%-86% for scenarios with strong treatment effects in the medium and high RecAP dose groups; between 66% and 67% for low dose groups with different responses and only when there was a strong treatment effect in the high dose group. As the sample size was determined based on the number of patients required for an intention-to-treat (ITT) analysis, patients who were randomised and subsequently withdrawn before completion of the study were not replaced.
[0198] According to the study protocol, the per-protocol analysis compared the intervention group with the placebo group for patients who received study drug and had no more than two missing ECC values on days 1 to 7, as detailed in the statistical analysis plan.
[0199] For descriptive statistics, continuous variables were expressed as means with standard deviations or medians with interquartile ranges, depending on their distribution. Normally distributed variables were compared using the Student's t test; the Mann–Whitney U test was used to compare nonnormally distributed variables. Categorical (and binary) variables were expressed as numbers with percentages and analyzed using the chi-square test. Survival analysis with Kaplan–Meier curves was used for graphical presentation. Cox proportional hazards regression analysis was used to estimate the hazard ratios for survival and RRT-free, shock-free, and mechanical ventilation-free days with RecAP versus placebo during study days 1–28.
[0200] The primary efficacy endpoint was analyzed by analysis of variance. All analyses of secondary endpoints were for exploratory purposes only, so no multiplicity adjustment was required. Post hoc multivariate analysis was performed to determine the robustness of the RecAP effect. All statistical tests performed on the intended treatment population (SAS software version 9.4; SAS Institute Inc., Cary, NC, USA) were two-sided, and the significance level used was 5%. result
[0201] Participants
[0202] Of the 326 patients who passed the initial screening, 301 were enrolled at 53 sites in 11 countries in the European Union and North America ( Figure 4Patients received RecAP 0.4 mg / kg (n=30), 0.8 mg / kg (n=32), 1.6 mg / kg (n=29 in Part 1 and n=82 in Part 2), or placebo (n=30 in Part 1 and n=86 in Part 2). In addition to minor baseline differences in renal function between the groups ( Figure 5 ), randomization produced a good balance of demographic and patient characteristics.
[0203] Security
[0204] Treatment-emergent serious adverse events were reported in 43% of patients receiving RecAP 1.6 mg / kg and 50% of patients receiving placebo. Fig.11 No RecAP dose-dependency was observed in the incidence and nature of adverse events (AEs). Anti-drug antibody titers were slightly above the detection limit in nine patients treated with RecAP.
[0205] discuss
[0206] In this multinational, double-blind, randomized, controlled trial involving patients with SA-AKI, we observed that the addition of RecAP to standard care had a large impact on survival, which was associated with improved and sustained recovery of renal function and long-term clinical outcomes, including the composite MAKE endpoint. Because this was a dose-finding, proof-of-principle, phase 2 trial, it was designed to include both studies related to renal dysfunction (e.g., short-term ECC) and long-term, more patient-centered clinical outcomes (e.g., MAKE 第60-90天 , survival rate)-related endpoints.
[0207] In conclusion, RecAP therapy was considered safe and well tolerated. In septic patients with AKI, RecAP therapy was observed to provide long-term improvements in renal function, MAKE 60-90 and significant improvement in survival rate. Example 2 Determination of RecAP enzyme activity and protein concentration
[0208] Activity assay:
[0209] The determination of recAP enzyme activity is based on the conversion (hydrolysis) of 4-nitrophenol phosphate to yellow 4-nitrophenol. The change in optical density at 405 nm per unit time is a measure of alkaline phosphatase activity. The assay buffer consists of 0.25 M glycine buffer at pH 9.6 at 25° C. with 2 mM MgCl2 and 0.1 mM ZnCl2 and 8.5 mM 4-nitrophenol phosphate.
[0210] The unit (U) definition of recAP, expressed in U / mL, is the amount of enzyme that hydrolyzes 1 μmol of 4-nitrophenolphosphate per minute at pH 9.6 and 25°C.
[0211] Protein concentration:
[0212] Determination of total protein concentration in RecAP drug substances and drug products was performed by UV / Vis analysis. RecAP solutions were analyzed at 280 nm and the absorbance was a measure of the protein content (mg / mL) using the following formula: Concentration (mg / mL) = [A / (a×b)]×DF where A = A280; b = path length; a = mass extinction coefficient of 1.01 mL mg-1 cm-1; DF is the dilution factor. Example 3 Explore the P / F Ratio
[0213] In preparation for studies on potential beneficial effects in the treatment of COVID-19, it was of interest to explore the effects of recAP (recombinant alkaline phosphatase) on relevant biomarkers or endpoints observed in the STOP-AKI study as described in Example 1 and Pickkers et al. (JAMA 2018). One of the relevant endpoints is the ratio of arterial oxygen tension to inspired oxygen fraction, i.e., P / F ratio. Therefore, the aim of this study was to explore the potential effects of recAP on the P / F ratio observed in the STOP-AKI study.
[0214] The relevant tables of the Analytical Data Model (ADaM) datasets provided by AM-Pharma, in particular the Adverse Drug Reaction (ADRe) dataset, were read into the statistical analysis program R (r-project.org; version 3.4.4 (2018-03-15)). The patient population randomized to placebo or 1.6 mg / kg recAP with a P / F ratio measurement was included. PEEP was at least 5 cm H2O for all patients with a P / F ratio measurement of 300 or less, as described in the Berlin 2012 definition. The baseline P / F ratio values determined in the screening sample and the samples collected on Day 1 were averaged to increase the stability of the values and reduce the occurrence of missing values and were labeled as MeanBase; patients with missing MeanBase values were excluded from the analysis. Absolute and normalized values were plotted as a function of time after the initial dose. Graphical exploration was also repeated after subsetting to tertiles of the MeanBase values. Means were plotted together with bootstrapped confidence intervals. The trends observed in these graphs were examined using linear regression and, at relevant time points, using nonparametric tests.
[0215] Figure 12-14Provided is the progression over time of the ratio of arterial oxygen partial pressure to fraction of inspired oxygen (i.e., the P / F ratio) after the start of treatment. When considering the complete data set, the absolute P / F ratio does not change in a particular way over time and there is no significant difference between the placebo and treatment groups, see Fig.12 . Due to death or discontinuation of the study for other reasons, the number of patients decreased over the course of the study and the width of the bootstrap confidence intervals increased accordingly. However, if the P / F ratio for each patient was determined as the "fold change" relative to the baseline value, patients administered recAP showed an increase over time compared to patients treated with placebo ( Fig.13 ).
[0216] As Fig.14 can be seen, this difference between recAP-treated patients and placebo-treated patients was mostly attributable to those patients with a P / F ratio below 200 mmHg at baseline (i.e., patients with moderate to severe ARDS), while only minor, transient differences were seen in the mild ARDS group (200 mmHg < P / F ratio < 300 mmHg) and the group of patients without ARDS shown at baseline (P / F ratio > 300 mmHg). In summary, those patients with moderate to severe ARDS (P / F ratio < 200 mmHg) at baseline benefited most from recAP treatment.
[0217] As Fig.15 can be seen, in a group of patients with moderate to severe ARDS (P / F ratio < 200 mmHg) at baseline, treatment with alkaline phosphatase resulted in a significant reduction in mortality when compared to placebo-treated patients with a P / F ratio < 200 mmHg. Accordingly, in one embodiment, provided is an AP for use according to the uses described herein, wherein administration of at least one dose of the AP results in a reduced risk of death of the subject. In a preferred embodiment, the reduction is a reduction in the all-cause risk of death. Preferably, the risk of death of the subject is reduced relative to when the subject is not treated with the AP. Also provided is an AP for use according to the uses described herein, wherein administration of at least one dose of the AP results in a reduced mortality rate in a group of said subjects. In a preferred embodiment, the reduction is a reduction in the all-cause mortality rate. Preferably, the mortality rate in the group of subjects treated with the AP is reduced relative to a group of subjects with severe to moderate ARDS not treated with the AP.
[0218] Mortality rate, risk of death, all-cause mortality rate, and all-cause risk of death have their usual meanings in the context of the present invention. In this context, the mortality rate or all-cause mortality rate means the mortality rate from all causes of death in a given population over a given period of time. In this context, the risk of death or all-cause risk of death means the risk of death from all causes in an individual over a given period of time.
[0219] It should be understood that the Detailed Description section, and not the Summary and Abstract sections, is intended to be used to interpret the claims. The Summary and Abstract sections may set forth one or more but not all exemplary embodiments of the present invention as contemplated by the inventors, and thus, are not intended to limit the present invention and the appended claims in any way.
[0220] The present invention has been described above with the aid of functional building blocks that illustrate the implementation of specific functions and their relationships. For ease of description, the boundaries of these functional building blocks are arbitrarily defined in this article. As long as the specified functions and their relationships are properly performed, alternative boundaries can be defined.
[0221] The above description of specific embodiments will fully reveal the general nature of the present invention, so that others can easily modify and / or adjust the various applications of these specific embodiments without excessive experiments by applying the knowledge in the art, without departing from the overall concept of the present invention. Therefore, based on the teaching and guidance presented herein, such adjustments and modifications are intended to be within the meaning and scope of the equivalents of the disclosed embodiments. It should be understood that the phrases or terms herein are for the purpose of description rather than limitation, so that the terms or phrases of this specification will be interpreted by those skilled in the art according to teaching and guidance.
[0222] The breadth and scope of the present invention should not be limited by any of the above-described exemplary embodiments, but should be defined only in accordance with the following claims and their equivalents.
[0223] All publications, patents, patent applications and / or other documents cited in this application are incorporated herein by reference in their entirety for all purposes to the same extent as if each individual publication, patent, patent application and / or other document was individually indicated to be incorporated herein by reference for all purposes.
Claims
1. Alkaline phosphatase (AP) for use in a method of treating acute respiratory distress syndrome (ARDS) in a subject in need thereof, wherein the subject has moderate or severe ARDS.
2. The AP for use according to claim 1, wherein the subject suffers from moderate or severe ARDS with a P / F ratio of ≤200 mmHg when measured using a minimum positive end expiratory pressure (PEEP) of 5 cmH2O.
3. The AP for use according to claim 2, wherein the subject suffers from severe ARDS and has a P / F ratio of ≤100 mmHg before treatment with the AP.
4. The AP for use according to claim 2, wherein the subject suffers from moderate ARDS and has a P / F ratio of >100 and ≤200 mmHg before treatment with the AP.
5. The AP for use according to any one of claims 1 to 4, wherein the AP is administered in at least one dose of 500 U / kg to 2,000 U / kg.
6. The AP for use according to any one of claims 1 to 5, wherein the ARDS is associated with or caused by sepsis.
7. The AP for use according to any one of claims 1 to 6, wherein the ARDS is associated with or caused by a viral infection.
8. The AP for use according to any one of claims 1 to 7, wherein the AP is a human AP.
9. The AP for use according to any one of claims 1 to 8, wherein the AP is a recombinant AP, preferably wherein the recombinant AP is chimeric.
10. The AP for use according to any one of claims 1 to 9, wherein the AP has at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence of RecAP (SEQ ID NO: 1).
11. The AP for use according to any one of claims 1 to 10, wherein administration of the AP results in an increase in respiratory function, preferably wherein the increase in respiratory function comprises an increase in the P / F ratio of the subject relative to the P / F ratio of the subject not treated with the AP.
12. The AP for use according to any one of claims 1 to 11, wherein the AP treatment is started within 48 hours after detection of ARDS.
13. The AP for use according to any one of claims 1 to 12, wherein the administration of the at least one dose of AP results in a reduction in the duration of or cessation of mechanical ventilation therapy in a subject undergoing mechanical ventilation therapy.
14. The AP for use according to any one of claims 1 to 13, wherein the AP is administered once a day.
15. The AP for use according to any one of claims 1 to 14, wherein the AP is administered intravenously.
16. The AP for use according to any one of claims 1 to 15, wherein the AP is administered in a dose three times a day.
17. The AP for use according to any one of claims 1 to 16, wherein the dose of the AP is 0.8 mg / kg or 1.6 mg / kg of RecAP.
18. The AP for use according to any one of claims 1 to 17, wherein the dose of the AP is 500 U / kg or 1000 U / kg of RecAP.
19. The AP for use according to any one of claims 1 to 18, wherein the administration of the at least one dose of the AP results in the subject's P / F ratio being maintained or increased.
20. The AP for use according to any one of claims 1 to 19, wherein administration of the at least one dose of the AP results in a reduced risk of death in the subject.
21. The AP for use according to any one of claims 1 to 19, wherein administration of said at least one dose of AP results in a reduction in mortality in a group of subjects including said subject.
